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Abstract 
Within the last two decades interest has been generated 
regarding the biochemistry, physiology and metabolism of omega-3 
fatty acids. They appear to have a variety of biological actions that 
influence platelet aggregability, inflammation, lipid levels and blood 
pressure. The low incidence of cardiovascular disease and certain 
inflammatory diseases found in the Greenland Eskimo population has 
been attributed to a diet rich in omega-3 fatty acids, particularly 
eicosapentaenoic acid and docosahexaenoic acid. It has been reported 
that absorption of omega-3 fatty acids can be altered by both the 
dosage form and the total amount of dietary fat consumed. 
To assess ways of enhancing the pharmacological effects of 
omega-3 fatty acid in man, we administered omega-3 fatty acids, 
providing 4.8 grams per day as eicosapentaenoic acid (EPA) for four 
weeks as either triglycerides (TG) or ethyl ester (EE) to four groups of 
IV 
six subjects whose diets contained either 20% (LF) or 40% (HF) of 
total calories from fat. All subjects were placed on a standardized run-
in diet with 40% of calories derived from fat for two week prior to 
receiving omega-3 fatty acids. Measurements included; food record 
analysis, lipid profile, bleeding time, fasting plasma phospholipids, 
serum thromboxane and urinary prostaglandins. 
The results of this study found a significant reduction (P~ 0.05) 
for the low fat groups compared to the high fat groups for percent of 
calories from fat, fat grams, saturated fat, polyunsaturated fat and 
monounsaturated fats. Body weight was stable for all subjects 
throughout the study. Lipid profiles detected no significant difference 
between the groups for total cholesterol (TC), low density lipoproteins 
(LDL), high density lipoproteins (HDL) except for triglycerides (TG) 
which were significantly lower following week one of fish oil 
supplementation. The greatest reduction for TC and LDL was found in 
the LFEE group with LDL increasing in the HFTG and HFEE groups. 
No significant differences were found in bleeding times (BT) at week 
one, except the LFEE group who had a slight increase. The LFTG 
group had the largest increase (P~ 0.05) in BT by week four. 
Significant increases (P~ 0.05) were found in all four groups for 
incorporation of EPA in plasma phospholipids at week one and week 
four 
Despite similar EPA incorporation into plasma phospholipids at 
week one, there was a greater conversion of EPA in the HFTG group 
than the LFTG, LFEE and HFEE into both TxB3 (mean 5.5 vs 1.7,1.2 
V 
and 1.5 ng/ml) and PGI3-M (mean 22.3 vs 11.4, 7.6 and 9.2 pg/mg 
creatinine). The LFTG group showed the largest reduction in serum 
TxB2 at week one (40% vs 19%, 23% and 30%) and was the only 
group to prolong bleeding time at week four at which time all four 
groups had similar reductions (40% vs 46%, 48% and 51 %). This 
data suggest BT increase was not closely related to TxB2 reductions. 
These results may be interupted to indicate that more PGI3 is 
formed from the same dose of dietary EPA if the EPA is delivered as a 
bolus of EPA enriched lipoproteins such as during post-prandial 
lipemia. This data suggest that both dosage form and total dietary fat 
influence the conversion of EPA to eicosanoids in man. 
KEY WORDS: fish oil, eicosapentaenoic acid, eicosanoids, 
prostacyclin, thromboxane 
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INTRODUCTION 
INTRODUCTION 
During the last decade, considerable research has been 
conducted to explore the beneficial effects of marine lipids rich in 
omega-3 fatty acids in human nutrition (1-4). These omega-3 fatty 
acids have been reported to exert a profound influence on several 
metabolic systems such as platelet aggregability, hypertension, blood 
viscosity and immune function (5-14). Twenty-carbon fatty acids with 
3-5 double bonds in appropriate configuration are precursors for 
prostaglandins, important local, chemical mediators that control nu-
merous physiological and biochemical activities. Prostaglandins are 
one group of autacoids in a larger family derived from 20-carbon 
(20=eicosa) fatty acids, known as eicosanoids. Previous investigations 
have ?emonstrated that a significant increase in dietary omega-3 fatty 
acids can potentially alter the synthesis of certain bioactive 
eicosanoids which appear to be influential in the pathological 
development of human diseases (15-20). 
Over the past 25 years great emphasis has been placed on the 
health aspects of dietary fat (21). High intakes of saturated fat, in 
particular, along with cholesterol have been labeled as the principle 
culprits for creating conditions of high risk for certain medical 
complications, including cardiovascular disease (22,23). The 
association for the development of heart disease has been attributed to 
the ability of dietary fat to elevate lipid and lipoprotein levels. The 
interaction of elevated lipids within the arterial endothelium, platelets 
1 
and monocytes is believed to influence the rate and severity of 
atherosclerosis (24). 
Americans today are confronted with diet problems different 
from those of their ancestors (25). It appears that dietary habits 
adopted over the past 100 years have contributed to the high 
incidence of chronic disease such as coronary heart disease, 
hypertension, diabetes and certain cancers (26). Compared to their 
ancestors, Americans today consume a much higher total fat intake 
including saturated fat and omega-6 fatty acids with a relative 
reduction of omega-3 fatty acid (26). This imbalance could contribute 
to some of the current chronic disease states. 
Recently the United States Surgeon General's Report on 
Nutrition and Health (27) and the Executive Summary of the Diet and 
Health Report of the National Academy of Sciences (28) noted the 
\ 
magnitude of this problem and concluded that the consumption of 
foods high in fat remain a major concern for all Americans. Currently, 
North Americans consume an average of 7% of calories as linoleic acid, 
with a ratio of linoleic acid (18:2n6) to linolenic acid (18:3n3) of about 
10: 1 (24,29). The intake of of 18:2n6 is approximately five times the 
minimum amount required to prevent essential fatty acid deficiency 
(24). This amount is believed to be excessive and may have 
deleterious effects on important functions such as inflammation, 
tumor growth and, in particular, altering the balance between the 
bioactive eicosanoids, prostaglandins and thromboxanes (30,31,32 
33,34). 
2 
Bang and Dyerberg introduced data linking diets high in omega-
3 fatty acids with a lower incidence of cardiovascular disease in the 
Greenland Eskimos than seen in Europeans (33,35). These reports 
stimulated an interest in the scientific community to re-examine the 
roles of omega-3 and omega-6 fatty acids in the disease process (31). 
The low rate of ischemic heart disease in this population along with 
reduced plasma levels of cholesterol and triglycerides did not seem to 
result from a low fat diet but rather to the unusually higher ratio of 
omega-3 to omega 6 fatty acids in the Eskimo diet (21). 
Eskimos consume a marine food diet (400-500 g daily) 
containing 40% of calories as fat with 15 grams derived from omega-3 
polyunsaturated fatty acids (36,37). This unusual food consumption 
pattern was associated with a distinct reduction in linoleic (18:2n6) 
and arachidonic acid (20:4n6) concentration in plasma lipids and 
I 
platelets with a concurrent increase in n-3 fatty acids, 
eicosapentaenoic acid (20:5n3) and docosahexaenoic acid (22:6n3) 
(38,39). A significant replacement of arachidonic acid by 
eicosapentaenoic acid and docosahexaenoic acid in platelets was found 
along with an increase in bleeding times in this population (40). 
These findings suggest that the addition of the long chain fatty acids 
20:5n3 and 22:6n3 to the diet may have a major benefit on the 
incidence of cardiovascular disease. 
Clinical investigations have continued to increase our knowledge 
on the effects of long chain dietary fat in particular the omega -3 and 
omega- 6 fatty acid series and their metabolic products. Information 
3 
exists regarding the potent effects of these important chemical 
mediators such as prostaglandins, leukotrienes and related 
eicosanoids and their important role in mediating cellular activity 
(9, 13, 14, 15,24). The list of diseases that are affected by eicosanoids, 
such as thrombosis, vasospasm, arthritis and immune inflammatory 
disorders continues to grow with the advancements in cellular biology 
(21). Understanding the role of omega-3 fatty acids and their 
influence on eicosanoid production and platelet activity may provide 
insights for developing theraputic modalities in the treatment of 
thrombotic disorders. 
It has been suggested that platelets produce excess 
thromboxane A2 in persons consuming relatively large amounts of 
linoleic acid (24). Dietary polyunsaturated fatty acids by conversion to 
their bioactive eicosanoids exert a much greater and more pervasive 
I 
effect on cardiovascular disease than earlier realized (41,42). Excess 
production of thromboxane A2 can have deleterious effects by 
increasing platelet aggregation and vasospasm (43). The pro-
aggregatory effects of thromboxane A2 are counteracted by production 
of prostacyclin by endothelial cells, which has vasodilatory and anti-
aggregatory effects (43). Inhibiting platelet thromboxane synthesis 
may be important in reducing the propensity to form arterial thrombi, 
as an initiator in myocardial infarction or ischemic stroke (44). As 
such, the suppression of thromboxane A2 and the enhancement of 
prostacyclin synthesis seems desirable to minimize these potential 
pathological events. 
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One means of reducing platelet thromboxane A2 production is by 
the selective reduction of arachidonic acid in the platelet 
phospholipids (24); investigations utilizing omega-3 fatty acids from 
seafood or fish oils have demonstrated reductions of erythrocyte and 
platelet linoleic acid and arachidonic acid with a concomitant increase 
in the content of eicosapentaenoic acid and docosahexaenoic acid in 
cellular membranes (45,46). Such lower ratio of arachidonic acid to 
eicosapentaenoic acid in platelet phospholipids is found in Eskimos 
(24). The omega-3 fatty acids of fish oils and to a lesser extent 
linolenic acid can inhibit the enzyme delta 6 desaturase and, thereby, 
reduce the conversion of arachidonic acid and linoleic acid to the pro-
aggregatory prostaglandin, thromboxane A2 (4). The decreased 
substrate availability of arachidonic acid through dietary manipulation 
in conjunction with competitive inhibition from omega-3 fatty acids 
\ 
results in a desirable reduction of thromboxane A2 synthesis. 
Designs of earlier investigations had failed to address the 
possible effects of high fat diets on the incorporation of dietary omega-
3 fatty acids into cell membranes and their eventual conversion to 
eicosanoid. Supplementation with omega-3 fatty acids usually is 
carried on in an otherwise unchanged typical Western diet (fat 35-
40% of total calories) (5,6,8, 13-18,20,47-63), or with slight 
reductions in fat (30% of total calories) (19,64-75) or without a 
complete description of the diet in the protocol except for fish or fish 
oil consumption (12,76-82). One study reduced fat intake to only 5% 
of total calories but failed to supply information on many relevant 
5 
biochemical parameters such as platelet activity (83). As such, high 
dietary fat consumption may alter the competition between 
arachidonic acid and eicosapentaenoic acid, thus favoring the 
arachidonic acid for cell membrane incorporation, for phospholipase 
A2 liberation and for metabolism by the cyclooxygenase resulting in an 
increase in thromboxane A2 production. 
A low fat diet supplemented with omega-3 fatty acids may 
enhance the metabolic environment by providing more favorable 
conditions for eicosapentaenoic incorporation and metabolism. 
Reducing the degree of omega-3 fatty acid "dilution" into total dietary 
fat may favor its competition with the abundant tissue stores of 
arachidonic acid, and result in a more desirable ratio of anti-
aggregatory vasodilatory prostacyclins (PGI2 and PGI3) to pro-
aggregatory vasoconstrictor thromboxanes (TxA2 and TxA3). In 
I 
addition, the thromboxane made from eicosapentaenoic acid (1'xA3) is 
believed to have much weaker biological activity than arachidonic-
derived thromboxane (TxA2) (4). To determine the endogenous 
biosynthesis of these autacoids, techniques have been developed to 
measure their specific urinary metabolites (84). The gas 
chromatography-mass spectrometry method is the most sensitive and 
specific method available and has been widely applied to quantitative 
studies of prostaglandin synthesis in animals and humans. 
In addition to the potential effect of dietary fat, the specific 
chemical structure of the omega-3 fatty acid, triglyceride or ethyl 
ester, may affect the incorporation rate as well as subsequent 
6 
prostaglandin production. The triglyceride structure of the omega-3 
polyunsaturated fatty acid in most fish lipids (EPA, DHA) tends to be 
preferentially acylated in the number 2 position of the triglyceride 
molecule. The ethyl ester form of the fish oil uses purified fatty acid 
ethyl ester as the vehicle for delivery of the fish oil in dietary studies. 
Comparative studies on triglyceride and ethyl ester omega-3 fatty acids 
are limited (85). Presently there is insufficient data to evaluate the 
benefits derived from either form. Further investigation is needed 
prior to making any recommendation to the general public. 
Increased knowledge of the interrelations of omega-3 and 
omega-6 fatty acid eicosanoid precursors, in conjunction with 
modulation of total dietary fat intake, should help define the · optimal 
dosing conditions to ~valuate potential beneficial effects of these 
unique polyunsaturated fatty acids derived from fish oil. The 
I information obtained from the present study will hopefully provide a 
better link between nutrition and health. 
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LITERATURE REVIEW 
LITERATURE REVIEW 
I. EPIDEMIOLOGICAL STUDIES 
Cardiovascular disease, including atherosclerosis and 
thrombosis, is the major cause of death in Western society today (4). 
Current research has indicated that diets high in fat and cholesterol 
are strongly correlated with the development of atherosclerotic 
coronary artery disease (86,87). Epidemiologic studies have similarly 
demonstrated that diets low in fat are linked with a lower incidence of 
coronary disease (88,89). Contrary to these findings, several recent 
studies indicate that certain ethnic populations consuming diets high 
in fat and cholesterol have a lower incidence of coronary heart disease 
(90,91).
1 
Studying these populations over the years has resulted in 
information suggesting that dietary changes may have a beneficial 
effect on the progression of cardiovascular diseases (85,86,92,93). 
Epidemiologic studies will be reviewed here to give an insight as 
to why there has been a resurgence of interest in omega-3 fatty acids. 
These studies will be presented in a manner to suggest how the 
potential benefit of consuming diets high in omega-3 fatty acids may 
relate to their effects on certain metabolic pathways. These data 
support the need for studying further this class of dietary fatty acids, 
particularly their effect on cell membrane incorporation with 
subsequent prostaglandin production. 
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The last decade of research on the possible benefits of omega-3 
fatty acids had been prompted by observations on Eskimo populations. 
Historically, Eskimos have been cited as a race with little evidence of 
atherosclerotic disease despite their high intake of fat and cholesterol 
(90,91). Investigators have demonstrated a wide variation of 
traditional diets among the different groups of Eskimos and their 
geographical locations (94-96). 
Anthropologists believe that contemporary Eskimos have 
descended from the Thule people, who migrated from Asia through 
Siberia and the Bering Strait to North America over 3000 years ago 
(97). Once reaching the northeast coast of Alaska, two paths of 
migration occurred: eastward toward the North Slope of Alaska and 
Canada and then on to Greenland and southward to the central inland 
zone and the western coastal regions. Data from two regions, Alaska 
and Greenland, demonstrate varied incidence of atherosclerotic 
disease, which may be the result of greater outside influence in the 
Alaskan population than seen in the Greenland population (94,95). 
Alaskan Population 
Eskimos are generally believed to have either a virtual absence of 
cardiovascular disease or to develop the disease at a much slower rate 
compared to Western populations. Only large, comprehensive series 
of post mortem examinations can accurately evaluate the severity and 
incidence of cardiovascular disease (98). The major limitations on 
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series from Alaska (and other primitive areas) include poor 
transportation and access to hospitals as well as numerous types of 
selection bias, discussed at length by the authors of such series (96). 
Two series of post mortem examinations were conducted and 
revealed a 5.8% (6 of 103) and 10.3% (35 of 339) cause for all deaths 
due to acquired cardiovascular disease (96,99). In addition, Gottman's 
study disclosed that 10% of the Alaskan Eskimo population had a 
significant degree of atherosclerosis (96). But, the degree of 
atherosclerotic development that was noted was of limited clinical 
significance and therefore did not account for the major causes of 
death which were of infectious nature, as is common among primitive 
people. Limitations, however, do exist in this type of reporting such 
as: sampling techniques which may introduce bias into · a series; 
methods of tissue collection; and, the reporting of cases such as 
sudden death in these remote villages, all of which may underestimate 
the deaths attributed to certain diseases (96). 
The two series of autopsy reports discussed above offered 
evidence to disprove the earlier belief in the lack of atherosclerosis in 
Eskimos. Dietary studies were therefore begun to explain this 
unusually low occurrence of atherosclerotic disease, reported in the 
early l 950's. Investigations of dietary intake from the food records of 
eight subjects were studied in Point Hope, Alaska (98). Dietary 
cholesterol intakes of between 420 to 1,650 mg/day were noted, thus 
illustrating wide individual variation. Average caloric intake was 3,000 
kilocalories (kcal), with a range of 2,300 to 4,500 kcal; 50% of 
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calories were provided from fat, 30%-35% from protein, and 15%-
29% from carbohydrate. Irrespective of these high intakes of 
cholesterol and fat of these eight individuals, the mean serum 
cholesterol concentration for the total study population of 168 
individuals was 221 mg/di, which tended to rise with increasing age. 
Scott et al (95) reported a slightly lower mean serum 
cholesterol level of 214.4 mg/di in 842 Alaskan Eskimos. It has been 
found that a large portion of Eskimos do not consume diets high in fat. 
As such, this low- or high-fat intake may reflect the seasonal food 
availability as well as geographical location; the main source of food 
being marine mammals for the northern Eskimos and fish for the 
southern Eskimos (96). 
The well-established hypothesis of a positive correlation 
between serum cholesterol and the increased incidence of 
cardiovascular disease was not upheld in the Point Hope, Alaska study 
population. Speculation of the unique observation for the relative low 
incidence of atherosclerotic disease despite the high fat and 
cholesterol intake in this Alaskan population could be explained by the 
following (98): 
1. The study population had a mean age of 26; 
cardiovascular disease does not usually manifest itself 
until after middle age; 
2. A serum cholesterol of greater than 250 mg/ di was 
rarely observed in the population, of which only 3% 
were over 40 years of age; 
1 1 
3. Some atherosclerotic changes were noted in the 
Eskimos' vasculature, but the mild plaguing did not 
present any clinical signs and symptoms. 
4. Variability existed in the availability of food sources, 
which may cause a periodic reduction in dietary 
cholesterol intake; 
5. The Eskimo alternation between hypercholesterolemia 
and hypocholesterolemia due to such variations in diet 
may have altered the net influx of cholesterol into the 
vasculature which is in contrast to US whites who have 
a constant influx of lipids into vascular walls; this 
alteration may allow for reduced atherogenesis in 
Eskimos. 
Greenland Eskimo Population 
The occurrence of ischemic heart disease is very low in the 
Eskimos of the Northern part of Greenland (90,91). Early medical 
studies in Greenland by Ehrstrom found the incidence of clinical 
manifestations of arteriosclerosis, in relation to the age-distribution, 
lower in Umanak in North Greenland than in the Korpo District in 
southeast Finland ( 100). Supporting these early data, a five-year 
review by Bang et al of the annual reports from the chief medical 
officer from the Umanak district of Greenland discovered only three 
cases of atherosclerotic disease and not a single case of diabetes 
12 
mellitus, which is a major stimulator of atherosclerosis in the United 
States. (91,101). Similarly, Kromann and Green's retrospective chart 
review of over 25 years reported 25 cases of apoplexy and only three 
cases of acute myocardial infarction (102). However, a higher rate of 
stroke is found in the the Eskimos than is seen in Danes. 
These results should be considered an underestimation since 
many fatal cases are not included and less serious cases may not have 
been hospitalized. Subsequent to these early reports, several studies 
were initiated to elucidate the mechanism responsible for this low 
incidence of vascular disease in the Greenland Eskimos. These 
investigations included utilization of more in-depth and controlled 
studies of nutrient intake (90), lipoprotein levels (91,103), plasma 
fatty acids (38), and the homeostatic characteristics of platelet 
physiology (39,40). 
Elevated cholesterol correlates highly with the development of 
ischemic heart disease in Western populations (104). Reports have 
indicated that lowering plasma total cholesterol and low density 
lipoproteins (LDL) in middle aged men with hypercholesterolemia 
reduced primary events (definite CHD death and/or definite nonfatal 
myocardial infarction) and mortality related to coronary heart disease 
(105,106). Population studies have illustrated a reduced incidence of 
heart disease concurrent with low serum lipid levels. Eskimos, with a 
low incidence of heart disease, have demonstrated variable levels in 
serum cholesterol based on their geographical location (95,98). The 
most urbanized Greenland communities were shown to have serum 
1 3 
cholesterol levels remarkably similar to the United States (91). 
However, detailed analyses of lipoprotein levels were lacking. 
Observations by Bang and Dyerberg contributed to the 
development of the initial hypothesis of Hugh Sinclair for the low 
incidence of heart disease by providing data on the plasma 
lipoproteins on the Greenland Eskimos (Table 1) (91). One hundred 
and thirty Eskimos, 69 women and 61 men, were included in the 
study. Significantly lower levels of total cholesterot triglycerides (TGL 
very low density lipoproteins (VLDLL and low density lipoproteins 
(LDL) were found in the Eskimo group when compared to an age- and 
sex-matched Danish control group. The most pronounced differences 
were found for TG and VLDL, with observable differences also seen in 
cholesterol and LDL. 
Sharper differences were noted in lipid parameters when 
comparing the Eskimo women of Greenland with Eskimo women now 
residing in Denmark (91). Overall, there were significantly lower 
concentrations of total lipids, cholesterol, TG, LDL, and VLDL in the 
Eskimo females from Greenland than seen in those from Denmark. 
Furthermore, comparing Greenland Eskimo women now living in 
Denmark with Danish women showed only minor differences in the 
lipid parameters. This data confirmed earlier information stating that 
coronary atherosclerosis is a very uncommon disease among 
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TABLE 1 
PI.ASMA CHOLESTEROL AND TRIGLYCRIDE LEVELS COMPARISON 
OF MALE AND FEMALES OF GREENLAND ESKIMOS AND DANES 
STRATIFIED ACCORDING TO AGE (91) 
Plasma Cholesterol 
Males 
Age 
years 
31-40 
41-50 
51-60 
> 60 
Females 
Age 
years 
31-40 
41-50 
51-60 
> 60 
Eskimos 
mmol/1 (mg/ di) 
5.58 (216) 
6.18 (239) 
6.56 (254) 
5.93 (229) 
Eskimos 
mmol/1 (mp;/ di) 
5.26 (203) 
5.96 (230) 
5.83 (225) 
5.98 (231) 
Plasma Triglycerides 
Males 
Age Eskimos 
years mmol/1 (mg/ di) 
31-40 0.66 (59) 
41-50 0.62 (55) 
51-60 0.61 (54) 
> 60 0.68 (60) 
Females 
Age Eskimos 
years mmol/1 (mg/ di) 
31-40 0.41 (36) 
41-50 0.47 (45) 
51-60 0.54 (48) 
> 60 0.59 (52) 
Danes 
mmol/1 (mg/ di) p value 
6.28 (243) p<0.02 
7.31 (283) p<0.02 
7.26 (281) p<0.02 
7.00 (272) p<0.01 
Danes 
mmol/1 (mg/di) p value 
6.44 (249) p<0.005 
7.09 (271) p<0.02 
8.32 (322) p<0.001 
8.45 (327) p<0.001 
Danes 
mmol/1 (mg/di) p value 
1.15 (102) p<0.001 
0.65 (146) p<0.001 
0.32 (117) p<0.001 
1.35 (120) p<0.001 
Danes 
mmol/1 (mg/ di) value 
0.95 (84) p<0.001 
1.02 (90) p<0.001 
1. 10 (97) p<0.001 
1.30( 115) p<0.001 
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Greenland Eskimos. 
The investigation of the Greenland Eskimos' plasma lipids 
revealed significantly low levels of plasma cholesterol, triglycerides, 
low density lipoproteins and very low density lipoproteins when 
compared to Danish controls. In addition to these reduced lipid 
levels, Eskimos have also demonstrated an unusual dietary pattern, 
principally in the high consumption of meat (90,91). The main source 
of meat is derived from marine life such as seals, sea birds, small 
whales and fish, found to be high in omega-3 fatty acids. Research has 
indicated that fatty acid patterns in plasma lipids reflect the dietary 
sources of fatty acids ( 107). The possibility existed that the high 
consumption of maritime food would influence the fatty acid patterns 
in the Eskimo population. 
Biochemical analysis of the fatty acid composition of the plasma 
fatty acids in the Eskimo population was found to be dramatically 
different from other reference populations (38). The esterified fatty 
acid composition of the plasma fatty acids for linoleic acid was only 
one-third to one-half in the Eskimo group compared to the other 
Danish reference population (Table 2). On the other hand, the 
eicosapentaenoic acid normally found in small quantities in Western 
populations was a major constituent ( 16%) of the esterified fatty acids 
in plasma of the Eskimo study population. The information extracted 
from the studies of the lipid parameters in conjunction with the fatty 
acid analysis substantiate the unique compositional differences 
between the Greenland Eskimos and other Western populations. 
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TABLE 2 
COMPARISON OF SELECTED FATIY ACID COMPOSITIONS OF 
CHOLESTEROL ESTERS (CE), TRIGLYCERIDES (TG) , AND 
PHOSPHOLIPIDS (PL) IN THE GREENLAND ESKIMOS (GE), ESKIMOS 
LIVING IN DENMARK (DE), AND DANES (DD) (38) 
22:0 
Cholesterol esters I 18:0 I 18: 1 I 18:2 I 18:3 I 20:4 I 20:5 I 26:0 
GE 1.1 25.3 20.3 0 1.0 15.8 3.2 
DE 1.5 20.6 52.8 0.6 0.2 1.0 1.7 
DD 1.0 22.8 47.8 0.5 4.0 0.1 5.6 
22:0 
Tri~)ycerides I 18:0 I 18: 1 I 18:2 I 18:3 I 20:4 I 20:5 I 26:0 
GE 5.9 35.1 6.2 0.1 0.6 4.2 5.5 
DE 4.6 38.6 17.3 0.5 0.8 1.5 1.3 
DD 1.1 40.1 12.5 0.8 0.2 0 3.4 
22:0 
Phospholipids I 18:0 I 18: 1 I 18:2 I 18:3 I 20:4 I 20:5 I 26:0 
GE 19.6 15.9 6.6 0.0 0.8 7.0 7.1 
DE 16.3 16.1 22.6 0.0 1.3 0.7 2.8 
DD 17.2 15.4 21.0 0.5 8.0 0.2 3.0 
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The reduction of lipid levels and the unique fatty acid patterns may be 
two contributing factors for the reduced incidence of heart disease in 
the Eskimo population. However, other possible areas, such as 
genetics and lifestyle, need to be evaluated before a definitive answer 
could be given to this association. 
Reasons for these distinct differences between Greenland 
Eskimos and Danes may be attributed to environmental factors such as 
genetics or lifestyle. The genetic influence, however, appears to have 
provided a weak explanation for the observable differences in these 
two populations (90). To determine the possibility of genetics, a 
crude, unpublished evaluation discussed by Bang and Dyerberg, looked 
at the racial characteristics of Eskimos (91) .. The unknown and 
varying degree of mixing of the Eskimos with other races could 
potentially affect the study outcome on heart disease. Lipid analysis 
comparing the "pure" with the "mixed" Eskimos, based on geometry 
of the eye, found no major difference. This study along with the data 
from the Greenland Eskimo women now living in Denmark do not 
support the genetic theory but instead points towards an 
environmental influence such as lifestyle or diet. 
The Eskimo lifestyle is equated with greater physical activity and 
an unusual dietary pattern compared to the Danish population (91). 
This could be attributed to the amount of time spent hunting and 
fishing. The increase in physical activity might possibly explain some 
of the differences in the lipid values, since increased physical activity 
has been associated with altered lipid parameters (108). Genetics and 
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physical activity did not appear to account for the low lipid levels in 
this population. Subsequently, research was directed toward the 
possible role of dietary factors in producing such differences. 
August Krogh, after performing metabolic studies in 1908 on the 
Greenlandic Eskimos stated, "the Eskimos are probably the most 
exquisitely carnivorous people on earth, as they dine almost 
exclusively on meat and fish" ( 109). Subsequent to this initial 
observation, Hugh Sinclair in 1944 pointed out the rarity of 
cardiovascular disease in the Eskimo population (110) Thus, even 
with the high fat intake, the unique dietary composition must be in 
part responsible for the reduced levels of lipids and lipoproteins. 
A higher intake of protein, equal amounts of fat, and fewer 
carbohydrates are found in the diets of Arctic communities · compared 
to Western populations (110). The high protein intake has been 
attributed to the large quantities of meat consumed from seal and/or 
whale meat, approximately 400 grams/day (90). The daily caloric 
intake from meat by the Greenland Eskimos is 2.5 times greater than 
that seen in the Danish population (38). However, one of the most 
pronounced differences in the Eskimo population dietary habits 
compared to Western society is the relatively high intake of the long-
chain polyunsaturated fatty acids, eicosapentaenoic acid and 
docosahexaenoic acid commonly found in maritime food sources. 
Continued research by Bang et al illustrated the dietary 
composition of the Eskimo population, focusing on the fatty acid 
composition of major food sources (90). The fatty acids supplied in 
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the diet provided the possible missing link for the low incidence for 
occlusive coronary heart disease. Analyses demonstrated that linoleic 
acid was considerably lower in the Eskimo groups when compared to 
the Danish group, but the intakes of eicosapentaenoic acid and 
docosahexaenoic acid were substantially higher when compared to the 
Danes (Table 3). The eicosapentaenoic acid and docosahexaenoic acid 
intake combined were 4.5 % of total fatty acid derived from food for 
Eskimos compared to 0.7% for the Danes. 
To further explain the lower cholesterol levels among Eskimos, 
researchers turned to the Keys equation ( 111). This equation has 
been used to demonstrate the f1:1nction of the dietary intake of 
polyunsaturated fatty acids (PUF A) relative to saturated fatty acids 
(SFA) and their effects on serum cholesterol. The formula for the Keys 
equation is as follows: 
Chol= 2.7 (S - 1/2 P) + 1.5 (C2 - Cl) 
where S and P are the caloric percentages of SFAs and PUFAs, 
respectively, omitting stearic acid, and C 1 and C2 are mg 
cholesterol/ 1000 calories in the two diets to be compared. This 
equation was derived from studies on European populations, and it is 
worthwhile to note that it does not predict the relationship between 
changes in dietary fats and cholesterol among Japanese subjects 
(88,89). Bang applied this formula to the change from Danish food to 
Eskimo food which caused the serum cholesterol levels to fall 
7.6mg/100ml (90). This result was not in accordance with the much 
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TABLE 3 
AVERAGE PERCENT OF TOTAL FATIY ACIDS IN FOOD OF SEVEN 
ESKIMOS COMPARED WITH MEAN VALUES FOR COMMON DANISH 
FOOD (90) 
Oleic 
Linoleic 
Linolenic 
Arachidonic 
Eicosapentaenoic 
Docosahexaenoic 
2 1 
Eskimos 
29.7 
4.7 
0.4 
0.1 
2.3 
2.2 
Danes 
29.2 
10.0 
2.0 
0 
0.4 
0.3 
lower cholesterol levels found in the Eskimo population (91). As such, 
this formula failed to explain the relatively low serum cholesterol 
levels found in the Greenland Eskimos' diet when compared to Danish 
food consumption. 
Another factor to consider involved the even more profound 
reduction in triglycerides among Eskimos compared to the Danish 
population. Food studies (38,90) have revealed a relatively low intake 
of carbohydrates with a simultaneously high intake of PUFAs - a 
pattern that may affect the metabolism of triglycerides and very low 
density lipoproteins (VLDL). Grundy has reported a 
hypotriglyceridemic effect associated with the consumption of PUFAs 
(112), which is especially relevant as the cholesterol reduction noted 
in Eskimo studies could be linked to that of reduced triglycerides. 
Thus, the reduced incidence of cardiovascular disease in the Eskimo 
population was apparently related to the large consumption of 
maritime food rich in omega-3 fatty acids, with a lower ingestion of 
omega-6 fatty acids, saturated fatty acids and carbohydrates. 
The Greenland Eskimo population has provided evidence for a 
possible preventative dietary component, which may reduce the 
incidence of chronic diseases associated with Western dietary habits. 
Bang, Dyerberg and associates, through epidemiological investigations, 
have increased the awareness of medical researchers of the potential 
benefits related to the omega-3 fatty acids, eicosapentaenoic acid and 
docosahexaenoic acid. This information has prompted other 
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investigators to explore the potential beneficial influence of these 
unique long chain fatty acids in other population-based studies. 
Cross Cultural / Cohort Studies 
More in-depth and comprehensive cross-cultural studies 
provided an opportunity to study the relationship between dietary fat 
and coronary heart disease mortality. Also, within-population studies 
have enabled investigators to study the relationship between omega-3 
fatty acids and cardiovascular disease on an individual evaluation. 
These studies are reviewed to provide information on the benefits 
which may be associated with a low fat diet and fish consumption. 
Studies conducted in Norway evaluated the proportion of deaths 
attributed to diseases of the circulatory system between 1940-1945 
(113). Mortality figures indicated a steady rise in mortality from 
circulatory disease until 1940, just before the war. But from 1941 
there was a sharp decline in deaths from circulatory diseases with the 
lowest figures in 1943-1945, during the war years. Dietary studies 
have shown that during this period there was a considerable decline in 
the consumption of meat, meat products and dairy products, high in 
saturated fat and cholesterol and an increase in fish, skimmed milk, 
cereals and vegetables, low in saturated fat and cholesterol. Average 
caloric intake per man fell from 3470 per day in 1936-1937 to 2850 
per day in 1942-1945. Caloric reduction was attributed to the 
decrease in fat intake which fell from 159 g per day to 71 g per day. 
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This study indicated the potential role of fat in the incidence of 
chronic disease and the possible influence of the ratio of omega-3 to 
omega-6 by reducing total fat, decreasing omega-6 and increasing 
omega-3 through fish consumption in the diet. 
The Seven Countries Study investigated the relationship 
between diet and cardiovascular disease ( 114). Examination included 
sixteen cohorts in seven selected countries: Finland, Greece, Italy, 
Japan, the Netherlands, the United States, and Yugoslavia. The fifteen 
year follow-up provided the opportunity to evaluate fish consumption 
data collected at baseline from food records to heart disease mortality 
( 115). The data suggested a weak non-significant correlation between 
fish consumption and cardiovascular disease. 
The six cohorts demonstrating the lowest mortality . rates for 
coronary heart disease had a wide range of fish consumption, between 
20 and 200 grams per day. This information may suggest that at any 
level of consumption fish may not be protective for heart disease. 
Early reports of this study did show that saturated fat is strongly 
correlated to the 15-year mortality from coronary heart disease ( 114). 
Of note, the strongest negative correlation for coronary artery disease 
was with red wine intake. These data add further support for 
illustrating the hypercholesterolemic effects of saturated fat. 
However, even increased fish consumption as part of a diet high in 
saturated fat does not prevent coronary heart disease 
Another cross cultural study was conducted on 21 countries to 
evaluate the relationship between fish intake and coronary heart 
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disease ( 116). This study initially indicated a moderate negative 
association between fish consumption and heart disease. But, further 
analysis of the data indicated that the negative correlation was 
dependent on the information provided by the Japanese data. The 
Japanese, who demonstrate a relatively low incidence of heart disease, 
are a group of people who consume approximately 100 grams of fish 
per day. Exclusion of this data, however, reduced the correlation 
between fish consumption and coronary heart disease mortality. In 
addition, multiple regression analysis of all 21 countries showed no 
relation between fish intake and heart disease when milk products 
and meat were included. The disadvantage of this study was that it 
used per capita fish consumption rather than real intake values, which 
thus included waste as well as consumed flesh. Also, the data provided 
information on age-adjusted mortality for males only. 
Additional surveys have been conducted on the Japanese 
population (88,89, 11 7). Epidemiological studies have been 
undertaken on Japanese men living in three areas: Japan, Hawaii and 
Los Angeles as well as within country comparisons. These studies 
indicate a low fat intake, less than 40% of calories, in the Japanese 
living in Japan when compared to those living in Hawaii and Los 
Angeles. In addition to the low fat intake, the major source of fat in 
the diet is derived from fish and marine invertebrates. Thus, this low 
fat intake in conjunction with high fish consumption in this population 
may be responsible in part for the low incidence of coronary heart 
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disease. One must keep in mind this population exhibits an 
excessively high rate of stroke. 
Epidemiological data has also provided information to disprove 
this association of reduced incidence of heart disease with an increase 
in fish consumption. Simonsen et al, studied two communities in 
Northern Norway, a coastal and an inland area (118). Evaluation of fish 
consumption revealed a 2.5 times greater intake in the coastal 
community compared to the inland population, 126.4g and 53.2g 
respectively. Daily intake of omega-3 fatty acids was 0.6g in the inland 
and 2.2g in the coastal area. Eicosapentaenoic acid was 0.25g in the 
inland community and 0.90g in the coastal area. The community with 
a high fish consumption had a higher incidence of cardiovascular 
mortality compared to a community with opposite dietary fat. 
However, these results may be obscured by other dietary factors such 
as sodium. 
The content of omega-3 fatty acids, particularly 
eicosapentaenoic, in a high fish diet has been proposed as the possible 
protective mechanism for heart disease. The study in Northern 
Norway demonstrates that the diet may be high in fish but low in 
eicosapentaenoic acid. Studies needed to be done to re-evaluate a diet 
either low or high in fish but with an inverse amount of omega-3 fatty 
acids. Other factors may be involved such as a low omega-3 to omega-
6 ratio or a high total fat intake which could possibly circumvent any 
potential benefit derived from omega-3 fatty acids. 
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To help understand these phenomena, additional 
epidemiological studies have been undertaken to investigate the effect 
of fish consumption on an individual level. The Zutphen study (119) 
followed 852 men initially free from obvious coronary heart disease for 
20 years. The average fish consumption of the Zutphen men was 20 g 
per day of which one third consisted of fat fish (e.g. herring and 
mackerel) and two thirds consisted of lean fish (e.g. cod and plaice). 
About 19% of the men did not eat fish. Mortality rates from coronary 
heart disease were two times lower among men who ate at least 30 
grams of fish per day compared to those who ate no fish. Similarly, a 
re-analysis of the Western Electric study (120) found an inverse 
relationship between fish consumption and mortality from coronary 
heart disease during 25 years of follow-up on 2,000 men ages 45-55. 
The average fish consumption by these men in Chicago was similar to 
that in the Zutphen trial. However the Chicago study failed to report 
the type of fish consumed. 
Contrary to these investigations, two cohort studies in Hawaii 
(121) and Norway (122) found no relation between fish consumption 
and coronary heart disease. In Hawaii, twelve-year incidence rates for 
total and fatal coronary heart disease in relationship to fish 
consumption found trends that were not significant for both analysis. 
Also, a recent follow-up analysis of 11,000 young Norwegian men free 
from obvious heart disease for three years during the initial study, 
found a insignificant negative trend between increasing fish 
consumption and deaths from coronary heart disease. 
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Supporting these negative trends was a study conducted on the 
Taiwanese population (123). Cardiovascular disease is an important 
concern in Taiwan, accounting for a large proportion of both morbidity 
and mortality after middle age. Studies comparing the fishing village 
with the agricultural population indicate a higher prevalence of high 
blood pressure in the fishing village. This population appears to have 
had little if any exposure to Western culture. The fishing community 
was extremely poor, had a high energy expenditure and consumed few 
fresh foods. However, fish was consumed often but was eaten salted 
due to preference and preservation. Even with this intake of fish and 
activity level, cardiovascular mortality was high. Therefore, other 
factors such as sodium may adversely affect any possible benefits from 
increased fish consumption. 
Discrepancies continue to exist among these epidemiological 
studies. Fish consumption and other factors, such as sodium and 
activity level, may affect the outcome for cardiovascular disease. One 
study did provide evidence that at lower levels, 30 grams per day, a 
reduction in the incidence of heart disease can occur, but at levels 
between 55 grams and 134 grams, no protective effect was found. 
However, Kromhout has suggested that at higher levels (200-400 
grams per day), a reduction of heart disease may also occur (124). 
Additional studies must be conducted to determine the exact 
mechanism responsible for the reduction in coronary disease found in 
these epidemiological studies as it relates to the metabolic function of 
omega-3 fatty acids. Determination of the amount of this 
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polyunsaturated fat in the diet is of utmost importance. The 
consumption of proper levels could optimize the desired responses 
such as a reduction in coronary disease. However, the metabolic effect 
of omega-3 fatty acids in conjunction with other dietary fats and total 
fat intake must be evaluated in order to better understand their 
metabolism, cell membrane incorporation and subsequent 
prostaglandin production so that optimal regimes for their dietary 
supplementation can be devised. 
II. BIOCHEMISTRY AND PHYSIOLOGY OF FATTY ACIDS 
Epidemiologic studies on certain populations, such as the 
Eskimos and Japanese, have reported a low incidence of heart disease 
and dietary habits which differ from that in industrialized Western 
countries (88-91). Western populations have a high salt and high total 
fat intake in particular saturated fat and the polyunsaturated fat, 
linoleic acid compared to the populations studied. In addition to the 
varying amounts of fat intake the Eskimos and the Japanese generally 
consume more fish than their Western counterparts. This maritime 
food source has been shown to be the major contributor of omega- 3 
fatty acids. 
The biological effects of linoleic acid have been studied for many 
years, but the potential health benefits attributed to the long chain 
omega-3 fatty acids found in fish are only presently being explored 
(125). The present study was conducted to evaluate the effect of 
29 
dietary fat on the absorption of omega-3 fatty acids and their 
subsequent conversion to prostaglandins. To understand the 
metabolic pathways of dietary fat, in particular polyunsaturated fatty 
acids, the structure and metabolism will be reviewed: 
Fatty acid structure and nomenclature 
Fatty acids are the basic chemical building blocks of lipids. Fatty 
acids are long-chain organic acids varying in length from 4 to 24 
carbon atoms (126). They have a single carboxyl group and a long non-
polar hydrocarbon "tail" which has water insoluble or oily 
characteristics. Fatty acids occur in only low amounts in a free or 
uncombined form in cells or tissues, but are abundantly present in 
covalently bound forms. They are located in different lipid classes 
such as phospholipids or triglycerides from which they can be 
released by chemical or enzymatic hydrolysis. 
The classical structure of a fat is a triglyceride molecule 
containing one molecule of glycerol to which 3 molecules of fatty acids 
have been joined through an ester bond. Schematically the structure 
maybe considered as shown (figure 1). The triglyceride represents a 
family of molecules of varying fatty acid composition. The fatty acids 
may be either saturated or unsaturated; by definition, saturated fatty 
acids contains no double bonds. 
double bond are known as 
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Those fatty acids containing one 
monounsaturated and those 
FIGURE 1. Structure of a glycerol molecule and a 
triglyceride molecule. 
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with two or more double bonds are known as polyunsaturated or 
polyenoic fatty acids. Most natural fats are complex mixtures of simple 
and mixed triglycerides containing a variety of fatty acids differing in 
chain length and degree of unsaturation ( 126). 
The nomenclature of fatty acids is based upon the location of the 
double bonds in the molecule (127). The description of the fatty acid 
is based on the position of the double bond and the method of 
numbering the carbon atoms. The carbon atoms of the fatty acid are 
numbered either from the carboxyl end or from the terminal methyl 
end. One of the more common methods involves counting the carbon 
atom from the carboxyl end. However, another method more 
commonly used by biochemists, involves numbering the carbon atoms 
from the terminal methyl end. The later method is employed when 
studying the relationship between fatty acid involvement and 
prostaglandin production. 
Double bonds are generally not found before the third carbon of 
the terminal methyl carbon, but may occur starting on the third 
carbon. This type of fat is usually referred to as omega-3 or n-3 fatty 
acids, such as y linolenic acid and eicosapentaenoic acid. Double bonds 
may also occur at the sixth carbon commonly known as omega-6 or n-
6 fatty acids, such as linoleic acid and arachidonic acid. However, 
double bonds occurring at the fourth or fifth carbons from the methyl 
end are rare in biological systems. It should be noted that these 
particular polyenoic fatty acids, omega-3 and omega-6 cannot be 
synthesized by human cells and as such must be provided by the diet. 
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Additions or subtraction of double bonds may occur, but may only 
be made from the position of the first double bond to the carboxyl end 
of the molecule (128). In addition to the changes in double bonds, 
fatty acids may be increased in length by the addition of extra pairs of 
carbon at the carboxyl end. Thus a fatty acid such as linoleic acid may 
start out with 18 carbon atoms and two double bonds and may be 
elongated to 20 carbons with four double bonds, arachidonic acid. (see 
diagram 2). Similarly, y linolenic acid may be converted to 
eicosapentaenoic acid and docosahexaenoic acid (see figure 2). The 
process of desaturation is controlled by the rate limiting enzyme Li 6 
desaturase and occurs primarily in the endoplasmic reticulum of the 
hepatocyte. 
Digestion and absorption of polyunsaturated fatty acids 
Approximately 90-98% of dietary fat consists of triglycerides, 
the rest comprising free and esterified cholesterol, and phospholipids 
(128,129). The majority of the triglycerides either from plant or 
animal origin contain saturated and unsaturated, medium to long chain 
fatty acids. The richest sources of the long chain unsaturated fatty 
acids, e.g., 18: 1 andl8:2 are derived from edible oils of plant origin. 
Coconut oil provides a rich source of medium chain triglycerides (CB-
C 12) with the dairy products supplying the short chain fatty acids (C-
4-C8). The ingestion of dietary fat elicits a multistage 
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Figure 2. Desaturation and elongation of omega-6 and 
omega-3 fatty acids. 
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metabolic process which may last for 16-24 hours if no other food is 
consumed (130) (see figure 3 for overview). 
Intraluminal digestion is initially preceded by the activation of 
lingual lipase on the mixed composition of dietary fat which is 
followed by further hydrolysis in the stomach by gastric lipases. Not 
surprisingly, studies in humans have indicated that gastric lipases may 
be more important than lingual lipase in the initial hydrolysis of fat 
(128). 
The entry of food from the stomach into the duodenum 
stimulates the enteric hormones, such as cholecystokinin, which 
causes the gall bladder to contract and release bile. These enteric 
hormones and pancreozymin also stimulate the secretion of juices 
which contain pancreatic lipases. It appears that the pancreatic lipase 
and salts of the bile acid conjugates are the most important factors in 
fat digestion (128). 
Pancreatic lipase is activated only at an oil-water interface and is 
specific for triglycerides containing long chain fatty acids and catalyzes 
the following reaction ( 128): 
TG + H20 ----- 1,2 diacylglycerol + fatty acid 
1,2 diacylglycerol + H20 ------ 2 acylglycerol + fatty acid 
The specificity of pancreatic lipase is almost entirely position 
dependent, regardless of the type of fatty acid, at position 1 and 3. 
The hydrolytic activity rate for this reaction, however, fs very slow. 
The main hydrolytic products of this reaction are 2- acylglycerides 
some di-acylglycerols, free fatty acids and free glycerol. 
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FIGURE 3: Overview of metabolism of dietary fat. (FFA; 
free fatty acids, LC; long chain) 
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Circulation 
The combination of monoacylglycerols and free fatty acids along 
with bile acids form the emulsifying system which breaks down fat 
particles and increases the surf ace area of triglyceride. Fat 
emulsification is important since the rate of lipolysis ·is dependent 
upon the surface area offered to the pancreatic lipase ( 128). 
Bile salts also function not only to promote emulsification and 
stabilization of pancreatic lipase but also to form micelles ( 128). 
Micelles are water-soluble macromolecular aggregates composed of 
monoacylglycerols, bile salts, free fatty acids and small concentrations 
of entrapped triglycerides. The micelles function primarily to shuttle 
lipids between the emulsion and the absorptive surface of the 
en terocyte. 
The metabolic process of fat digestion transforms dietary fat, a 
hydrophobic substance, into the more polar derivatives that can 
interact with water. However, the digestive process involving 
triglycerides of omega-3 fatty acids may not be the same as for other 
dietary fats ( 130). Early hypotheses had suggested that triglycerides 
containing omega-3 fatty acids were inefficiently hydrolyzed by 
digestive lipases ( 131-133). Other reports were conflicting as to 
whether the introduction of double bonds at the omega-3 position 
inhibited hydrolysis ( 134,135) However, these reports were based on 
a short incubation period, 15 minutes or less, and the partial 
hydrolysis of triglycerides was achieved using porcine pancreatic 
lipase. Ethyl ester form of omega-3 fatty acids also appears to be 
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poorly hydrolyzed by pancreatic lipase but may enter the enterocyte 
unhydrolyzed ( 136). 
The digestion of fat goes on for hours in vivo and the rate of 
lipolysis may have little influence on the ultimate amount of fat 
absorbed. There have been no direct studies on the in vivo efficiency 
of lipolysis on triglycerides containing omega-3 fatty acids. It has been 
suggested however that once triglycerides containing omega-3 fatty 
acids have been hydrolyzed and liberated they are totally absorbed in 
vivo (137-139). But studies in vivo are lacking to determine the effect 
of both lingual and gastric lipases on the hydrolysis of triglycerides 
containing omega-3 fatty acids. 
As the lipolytic products pass from the micelles in the intestinal 
lumen into the interior of the mucosal cell they must cross the 
unstirred water layer which is immediately adjacent to the lipid-
protein membrane of the microvilli. The major portion of fat 
absorptive activity is believed to occur in the jejunum with a minor 
contribution from the ileum (128). This uptake is mediated through a 
non-energy-dependent passive process. Once within the enterocyte, 
the hydrolytic products are re-esterified to triglycerides, 
phosopholipids, and cholesterol esters. 
The nature of the fatty acids, both their chain length and degree 
of saturation, influences the quantitative aspect of fat absorption ( 128). 
The longer-chain saturated fatty acids such as stearic acid are less 
completely absorbed than the shorter chain saturated fats or the more 
highly unsaturated fatty acids. Also, unsaturated fatty acids and 
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monoacylglycerols require a lower bile acid concentration for micellar 
solubilization than do saturated fatty acids and their monoacylglycerols 
which may influence their absorption rate. It should be noted that 
triglycerides are not incorporated into micelles in large amounts 
which may also partially account for their low absorption rate into the 
en terocyte ( 128). 
In addition to the influence of the length of the carbon chain on 
absorption, the degree of saturation demonstrates unique absorptive 
characteristics. Animal studies have indicated that meals composed of 
saturated fats are poorly absorbed when compared to an unsaturated 
counterpart of the same chain length (140). Feeding triglycerides of 
mixed composition were better absorbed in both humans and animls 
when compared to triglycerides of the same saturated fats: the higher 
the amount of saturated fat in the intact triglyceride, the smaller the 
amount of fat absorbed (141,142). Thus, both the degree of saturation 
and chain length affect fat absorption. 
Animal studies have demonstrated that the absorption rates of 
eicosapentaenoic fatty acid is equivalent to that of arachidonic acid 
(136,143). However, it appears that the chemical forms of 
eicosapentaenoic and docosahexaenoic acid affect its relative rate of 
absorption as compared with linoleic acid. Free fatty acid absorption 
is greater than that of the triglyceride form, and the triglyceride is 
absorbed more efficiently than the ethyl ester (139). But, the best 
method of omega-3 fatty acid administration remains unclear. Purified 
fatty acid esters of omega-3 fatty acids, such as ethyl and methyl ester, 
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have been utilized in experimental feeding studies (144, 145)), and 
EPA given in the form of ethyl esters appears to be totally absorbed 
( 146). Various studies have also provided data suggesting that omega -
3 fatty acids can be readily absorbed as free fatty acids or triglycerides 
following enzymatic hydrolysis (136-138, 143,147). 
Once within the enterocyte, the short chain fatty acids are 
transported directly into the portal blood as albumin-bound fatty acid. 
The medium chain fatty acids may be either reesterified into 
triglycerides within the enterocyte or be transported directly into the 
portal system. Once the absorptive process has occurred, the long 
chain fatty acids are activated to their CoA derivatives through the 
action of fatty acyl:CoA ligase located in the endoplasmic reticulum. 
Three pathways are available for the formation of triglycerides from 
the long chain fatty acids: monoacylglycerol, glycerol phosphate, and 
dihydroxyacetone phosphate (128). The long chain fatty acids are 
initially converted into triglycerides and subsequently become a part of 
a chylomicron for transport. 
The monoacylglycerol pathway utilizes the 2-monoacylglycerol 
formed during the hydrolysis of triglycerides in the intestinal lumen 
for further acylation. This involves the sequential transfer of acyl 
groups from acyl-CoA first to 2 monoacylglycerol and then another acyl 
group is transferred to the resulting diacylglycerol. The triglyceride 
formation from this pathway appears to be very similar to dietary 
triglycerides. Eighty-five percent of chylomicron triglycerides are 
synthesized in this manner. 
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The second pathway involves the action of glycerol kinase in the 
formation of glycerol-3 phosphate. The glycerol phosphate is acylated 
by means of a specific acyltransferase to form 1, 2 diacylglycerol 3 
phosphate and may be further converted to triglycerides or 
phospholipids. Approximately 15% of the triglycerides are formed 
from this pathway. 
The final and least utilized pathway, dihydroxyacetone 
phosphate, stimulates the incorporation of glucose into glycerides 
during fatty acid absorption. As such the products of glycolysis may 
furnish the glycerol for glyceride synthesis. The presence of glycerol 
kinase in the intestinal cells indicates that glycerol itself may be 
utilized for glyceride synthesis. On the other hand, glycerol itself may 
not used for for glyceride synthesis during fat absorption possibly due 
to the rapid absorption of glycerol at a site different from fatty acids. 
Phospholipids contribute a small but distinct part to dietary fat. 
The pancreatic juice provides the phospholipases necessary for 
phospholipid hydrolysis. Similar to digestion of triglycerides, 
phospholipids must be dispersed into small micelles of which bile 
acids are a necessary component in order for enzymatic hydrolysis to 
occur. Phospholipase A1 hydrolyzes the ester bond in position 1 of 
glycerol and phosopholipase A2 acts at position 2. As an example, 
lecithin is hydrolyzed to 1-acylglycerolphosphocholine (lysolecithin) 
by phosopholipase A2. 
Once entering the mucosal cell, the lysolecithin is partially 
reesterified to lecithin . The remaining lysolecithin is hydrolyzed to 
44 
glycerophosphocholine, glycerophosphate, glycerol and inorganic 
phosphate. The other hydrolytic products, fatty acids and glycerol, are 
reesterified into triglycerides. Both the fatty acids and 
lysophosphoglycerides are involved in chylomicron synthesis which 
allows their transport into the circulatory system. 
Intestinal cholesterol is derived from both the diet and from 
intestinal secretions and bile ( 128). Cholesterol from the diet may be 
either unesterified or esterified with fatty acids; cholesterol from bile 
is largely unesterified. Pancreatic cholesterol esterases are 
responsible for the hydrolysis of cholesterol esters to free cholesterol. 
In addition, bile salts are present to prevent synthesis and promote 
hydrolysis as well inhibit proteolytic digestion of the pancreatic 
cholesterol esterases. 
Prior to absorption into the enterocyte, free cholesterol must be 
solubilized. This is accomplished through incorporation into mixed 
micelles containing bile salts, fatty acids and lysolecithin. Cholesterol 
absorption however is limited (30-60% of dietary and intestinal 
cholesterol) which is dependent upon the presence of bile salts. Also 
the amount of fat may affect the absorption of cholesterol into 
micelles. Larger amounts of cholesterol are incorporated into micelles 
which have an increased amounts of fat (128). Once in the enterocyte, 
cholesterol is reesterified (80-90%) and incorporated into 
chylomicrons and transported into the intestinal lymph. 
The final transport of the lipids, triglycerides, phospholipids 
and cholesterol, from the cell involves the formation of chylomicrons 
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in the golgi complex. The enzymes associated with chylomicron 
formation are generally associated with the endoplasmic reticulum. 
The chylomicron is a large particle, approximately 0.5-1.0 um in 
diameter and is composed of about 90% triglyceride, with the 
remainder being made up of phospholipids and of both free and 
esterified cholesterol (128). Phospholipids with protein form a thin 
surface layer for particle integrity. The particle once outside the cell 
diffuses to the central lacteals and passes into the lymphatic 
endothelium. This process occurs either by passive diffusion through 
the endothelial gaps or by an active transport within pinocytic vesicles. 
The lymphatic system serves as the transport mechanism for the 
chylomicrons. The chylomicrons are transported to the superior vena 
cava via the thoracic duct where they reach the sites of utilization or 
storage through the systemic blood. 
The complex multiphasic process of complete digestion and 
absorption of dietary fat appears to be quite rapid (128). Normal 
humans appear to digest 95% of dietary fat. One study with the 
electron microscope has indicated that fat absorption resulting in 
secretion of the chylomicron into the intercellular space is achieved in 
approximately 12 minutes but may take over 12 hours to complete 
( 148). Once the digestive and absorptive process are completed the 
function of dietary fat varies according to metabolic needs. Dietary fat, 
particularly the long chain fatty acids arachidonic and 
eicosapentaenoic acid, play major roles in membrane structure as well 
as being precursors for powerful chemical mediators. 
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III. MEMBRANE FA TTY ACIDS 
Membrane composition has been correlated with many 
physiological and biochemical parameters, including immune 
response, platelet aggregation, membrane-bound enzyme activity, 
receptor affinity and transport of numerous compounds (149). There 
is a series of steps that exert an influence on the fatty acid 
composition of membrane phospholipids which differ not only from 
cell to cell but also with the type of polyunsaturated fatty acid present 
in the diet. The function of cell membranes depends on the 
interrelationship between lipid, protein and cholesterol as well as the 
types of fatty acids incorporated into cell membrane phospholipids. 
Alterations in membrane composition and function have been found to 
occur as a result of manipulation of dietary fat ( 150). 
The occurrence of long chain fatty acids in biological tissues has 
been known for many years. However, the function of the omega-3 
fatty acids with regard to specialized membrane activity is still quite 
uncertain. Omega-3 fatty acids are found primarily in biological tissues 
esterified to phospholipids, triglycerides, and cholesterol (150). 
Long chain fatty acids are components of phospholipids of all 
cellular membranes and serve as a major structural component of all 
interior and exterior biomembranes (129). The striking difference 
between phosopholipids and triglycerides are structural 
characteristics (128). Phospholipids are composed of hydrophilic 
and hydrophobic parts. Each phospholipid molecule contains a single, 
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relatively compact highly polar hydrophylic moiety, the "head" and two 
long flexible hydrophobic "tails". As the name implies this group of 
lipids contains phosphorus in the form of phosphoric acid esters. 
These structural distinctions may contribute to the behavior 
demonstrated by specific lipid classes. 
Phospholipid synthesis 
One phospholipid class of membrane amphiphilic lipids is 
derived from glycerol (128) (see diagram 4). The A1 group is derived 
from fatty acids and is in general saturated, unbranched with an even 
number of carbons (often 16 or 18). The biosynthetic process does 
not draw randomly from a mixed pool of fatty acyl groups. On the 
contrary, more unsaturated fatty acids are involved in the genesis of 
the A2 then the A1 moiety. 
The structure of phospholipids is well understood. Phosphatidic 
acids are monoesters of phosphoric acid and are the intermediates in 
the biosynthesis of other phospholipids. The more commonly known 
amphiphilic lipids are esters of phosphatidic acids in which the 
hydrophilic group contains a formal charge (s), a hydroxyl group (s) or 
both (see figure 4). The more familiar glycero phospholipids include 
phosphotidylcholine (PC). phosphatidylethanolamine (PEL 
phosphatidylserine (PS), and phosphatidylinositol (PI). 
The phosphatidylcholine, more commonly known as lecithin, 
occurs abundantly and is nearly ubiquitous in nature. About half of the 
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FIGURE 4 Structure and names of the major 
phospholipids. 
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fatty acyl group content of mammalian PC is saturated, principally 
16:0 concentrated in the sn-1 position (stereo-specific numbering of 
the glycerol-skeleton carbon atom) with most of the rest being derived 
from 18:1. Similar to PC, PE (commonly referred to as cephalin) 
saturated fatty acyl groups are located almost entirely in the sn-1 
position, but these are predominantly 18:0. Additionally the 
unsaturated fatty acyl groups in the sn-2 position are more richly 
polyenoic compared to the PC. 
The PS in mammalian tissues may be similar to the PC in the 
position of the fatty-acyl groups as well as other chemical 
characteristics. The distribution of the fatty-acyl groups in mammalian 
tissue of PI may resemble that of PE rather than PC with 50% 18:0 and 
30% polyenes. The fatty-acyl group composition of these 
phospholipids, PC, PE, PI, and PS in biomembranes is closely 
regulated with a major function of this group of lipids being to 
maintain optimal fluidity of the structures with in the organism. 
The biosynthesis of the PL involves a series of reactions utilizing 
several common pathways (128) (see figure 5). Biosynthesis of PC may 
occur from phosphatidic acid and activation by cytidine-diphosphate 
(CDP) of choline in conjunction with diacylglycerol. PE is formed 
through a set of similar reactions except for the involvement of CDP-
ethanolamine. However, the formation of PI has been proposed to 
occur through the activation of the CDP diglyceride rather than the 
CDP activation of inositol. 
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FIGURE 5 Pathways for the biosynthesis of 
phosphatidylinositol, 
phosphatidylcholine and 
phophatidylethanolamine 
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The major portion of phospholipid biosynthesis occurs through 
the CDP activation pathways. However, other alternative pathways 
exist as well as pathways specific to certain members of the this lipid 
group. The actual mechanism for the formation of PS in higher 
animals appears to be Ca++ stimulated exchange reaction principally 
involving PE. This appears to be a major but not the only exchange 
process for phospholipid synthesis. Base exchange may be another 
pathway for biosynthesis of phospholipids. This involves the regulation 
of the hydrophobic heads which appears to be a competitive reaction. 
Also, for this pathway affinity seems to be in the order 
serine>ethanolamine>choline. 
Understanding the pathways for the biosynthesis of this lipid 
group allows for a better appreciation of the nature of the biochemical 
structure of cellular membranes and subsequent chemical reactions. 
The reactions which occur within the biomembranes involving 
phospholipids are dependent upon both synthetic rates and the 
enzymatic activity of the various phospholipases. In addition to activity 
on membrane phospholipids, other phospholipases also play an 
important role in the digestion and absorption of phospholipids as 
previously discussed. 
The knowledge derived from the positionally-specific enzymatic 
activity of the phospholipases has provided for the opportunity to 
accurately determine phospholipid structure ( 128). Phospholipases 
exhibit a high degree of positional specificity (see figure 6). The 
phospholipases A catalyze the removal of the acyl groups from the 
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phospholipids. Phospholipase A1 removes the acyl group from sn-1 
and phospholipases A2 that from atom 2 both leaving a 
lysophosphoglyceride. 
The phospholipase A1 action releases mixtures of fatty acids that 
are more saturated which reflects a positional rather than acyl group 
specificity. Phospholipase A1 is widely distributed in nature and is 
dominant in the endoplasmic reticulum. 
Phospholipase A2 hydrolytic activity removes the acyl groups 
from carbon 2, which often are predominantly unsaturated. It is most 
active in the hydrolysis of PC and PE and less so on PS and PI. 
Phospholipase A2 is the major phospholipase in the mitochrondria. 
Several other phospholipases exist such as phospholipases B,C,D. 
Phospholipase B is a nonspecific term that has been associated 
with phospholipase Al, lysophospholipase and 1,2-deacylase. 
However, controversy exists as to the single enzymatic activity. 
Phospholipase C catalyzes the hydrolysis of the bond between 
diacylglycerol and phosphocholine in phosphatidylcholine but is less 
active on PE or PI. A major phospholipase in plant tissue is 
phopholipase D. It acts on phosphoglycertdes to form phophatidic 
acid and alcohol. 
These phospholipases exist in both soluble and membrane-
bound forms. and demonstrate maximal activity in vivo within or at the 
surface of biomembranes. They show little tendency to act on 
molecularly dispersed lipids, but act on aggregates of such substances. 
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FIGURE 6. Site of the hydrolytic activity of specific 
phospholipases on phospholipids 
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In addition to the enzymatic activity of the phospholipases on 
phospholipids, acyl transferases are present in biomembranes to 
transfer acyl groups from CoA to either sn-1 or sn-2 of the 
lysophosphoglycerides. These acyl transferases are widely distributed 
in most tissues and subcellular fractions. Such transacylation 
including the previous activity of a phospholipase A is quite specific for 
the type of acyl group and for the position to which it is to be 
transferred ( 128). 
It appears that rate of transfer of a saturated fatty acyl group is 
more rapid than an unsaturated acyl group for a 2 acylglycerol-3 
phosphate and a more rapid transfer of an unsaturated fatty acyl group 
to a l-acylglycerol-3 phosphate ( 128). The final result for positioning 
is a saturated fatty acid at the sn-1 position and of certain unsaturated 
fatty acids at the sn-2 position. In addition to ~he rearrangement of 
the fatty acyl groups through transacylation, it has been found that 
other alterations, desaturation and elongation, may take place within 
the membrane by membrane-bound enzymes (128). This process 
alleviates the need for the release of intermediate fatty acids to 
equilibrate with an external fatty acid pool. As such, desaturation of 
the acyl group may occur either by release from the phospholipid, 
desaturation and re-incorporation all within the membrane- or by 
desaturation of the fatty acid group of the intact phospholipid. 
Phospholipid composition of structures depend on a systematic 
process which may be summarized: 
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1. Synthesis of phospholipids involving specific fatty acid 
acylation; 
2. Deposition into the cellular membranes; 
3. Polar heads may be exchanged and alter the hydrophilic 
characteristics; 
4. Fatty acyl groups may be removed and replaced via the 
phospholipase acyl transferase route thus regulating 
characteristics attributed to the hydrophobic portion of 
the lipid membrane. 
Phospholipids are constantly remodeled by fatty acid alteration 
by membrane-bound enzymes. The types of fatty acids altering the 
structure of phospholipids have been shown to be dependent 
somewhat upon the availability of fatty acids present in the diet (151). 
The amounts of certain 20-carbon polyenoic fatty acids, within the 
membrane structures have been shown to influence the biosynthesis of 
important chemical mediators from these fatty acids ( 152). 
Arachidonic Acid 
Arachidonic acid is a 20-carbon fatty acid with 4 methylene-
interrupted double bonds, the last being 6 carbons from the omega 
end of the molecule. Arachidonic acid may be derived from the diet as 
a preformed fatty acid or the result of chemical alterations of 
precursors such as linolenic acid. Dietary linoleic acid is metabolized 
mostly in the liver via the rate-limiting step ll 6 desaturase to gamma 
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linoleic acid which is subsequently converted to arachidonic acid by 
elongation and desaturation ( 153) (see figure 2). Once the elongation 
and desaturation has occurred, the free fatty acid is transported from 
the liver bound to plasma albumin to platelets and megakaryocytes 
( 154). The desaturation of linoleic acid is slow but the uptake of 
arachidonic acid into cell membranes is rapid. This accelerated 
uptake of arachidonic acid demonstrates the preferential 
incorporation of the fatty acid into the phospholipid structure. This 
process offers an explanation for the low rate of oxidation of 
arachidonic acid as it is being preferentially incorporated into the 
stable pools associated with biomembranes ( 154). 
It has been observed that the incorporation of arachidonic acid 
was dependent upon specific events within each plasma phospholipid 
class rather than being reflective of the total quantity of arachidonic 
acid ( 152). PI demonstrates a rapid uptake of arachidonic acid but 
results in small quantities actually present. But, PE appears to show a 
slow incorporation with substantial amounts found in the class as a 
whole. It should be noted that in Western man arachidonic acid is the 
principle polyunsaturated fatty acid in the membranes of both platelets 
and blood vessel walls. 
Phospholipases and acyltransferases maintain strict control over 
the concentration of free, non acylated arachidonic acid in the tissues 
under normal circumstances ( 155,156). Low concentration of 
arachidonic acid is very important because it may influence the 
amount of free arachidonic released upon stimulation and thus affect 
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the synthesis of eicosanoids. The releasing action may be triggered by 
a variety of different receptor-mediated stimuli, through perturbance 
of the cell membrane including chemical or mechanical stimulation 
and through alteration of calcium and other cation gradients 
(152,154). 
Once released, arachidonic acid is rapidly metabolized to 
oxygenated products by two distinct pathways involving either 
lipoxygenase or cyclooxygenase enzymes ( 128) (see figure 7). 
Arachidonic acid maybe converted by lipoxygenases to various mono, 
di or tri hydroxy fatty acids via peroxy intermediates. The 5-peroxy 
arachidonate may be isomerized to form leukotriene ¼ which is then 
modified to form other leukotrienes. The leukotrienes are potent 
bioactive modulators, involved in pulmonary functions (asthma). 
allergies, macrophage function, chemotaxis, chemokinesis, 
inflammatory responses and immune function (4,128,157). 
Another arachidonate oxygenation pathway involves 
cyclooxygenase. Cyclooxygenase transforms arachidonic acid into an 
unstable intermediate endoperoxide, PGG2. This substance in the 
presence of tissue peroxidase and reduced glutathione, is further 
transformed to another unstable endoperoxide PGH2. Both PGG2 and 
PGH2 have half lives of about 5 minutes at 37°C. The endoperoxides 
also function to initially stimulate the cyclooxygenase in an 
autocatalytic manner. This activity results in a burst of eicosanoid 
synthesis once arachidonic acid becomes available thus ensuring an 
abundance of active material at the local receptor site. 
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Thromboxane A2 is the principle metabolite of arachidonic acid 
in platelets and is a potent vasoconstrictor and a stimulus for platelet 
aggregation (158). A specific isomerase, thromboxane synthase, 
transforms the cyclic endoperoxide PGH2 into thromboxane A2. In 
plasma, TxA2 is bound to albumin and has a half life of 30 seconds 
prior to hydrolysis to inactive thromboxane B2. Platelets have the 
inherent ability to synthesize large amounts of TxA2 after stimulation 
and as such may contribute significantly to the development of 
intravascular aggregation of platelets as well as arterial spasm (4). 
Prostacyclin (PGI2) is the major product of cyclooxygenase 
formed in the vascular endothelial cells (153). It is likewise the 
product of a specific isomerase prostacyclin synthetase, that converts 
PGH2 into PGI2. This substance is a potent vasodilator and is both a 
marked inhibitor of platelet aggregation as well as causing 
disaggregation of previously stimulated platelets. Prostacyclin has a 
half life of 2-3 minutes which spontaneous hydrolysis to a stable, 
inactive compound 6-keto-prostaglandin Fia• The effects of platelet 
aggregation are normally kept in check by PGI2, thus inhibiting the 
adherence of platelete aggregrates to blood vessel walls. The balance 
of these two autacoids, TXA2 and PGI2, appears to be critical due to 
their potential involvement in the development of atherosclerotic 
disease. 
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FIGURE 7. Pathways of arachidonic acid metabolism 
( 162). 5-HPETE: hydroperoxyeicosatetraenoic 
acid; PGG2, PGH2: PG endoperoxides; LTA4: 
leukotrienes A4; LTB4: leukotriene B4; PGI2; 
Prostacyclin I2; TxA2: thromboxane A2; 
TxB2: thromboxane B2. 
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Eicosapentaenoic and Docosahexaenoic Acids 
Similar to arachidonic acid, the dietary 20-22 carbon chain 
omega-3 fatty acids are rapidly absorbed and incorporated into 
biomembranes (45,46). Eicosapentaenoic and docosahexaenoic acid, 
desaturation and elongation products derived from a linolenic acid, 
and preformed compounds those of which are much more effective 
then a linolenic acid in increasing their content in phospholipids (46). 
Both eicosapentaenoic acid and docosahexaenoic acid compete 
for acyl transferase and competitively displace arachidonic acid from 
membrane phospholipids (46). Generally eicosapentaenoic acid 
displaces arachidonic acid mainly from PC with docosahexaenoic acid 
displacing it from PS and PE. However, the acyl group specificity 
varies markedly from cell to cell. 
With an increase in dietary omega-3 fatty acids concentration, 
(i.e. eicosapen taenoic and docosahexaenoic acid), phos pholi pid 
concentration of arachidonic acid and linoleic acid decrease 
(49,50,51,77). A study conducted on human volunteers demonstrated 
the ability to alter membrane fatty acids through dietary intervention 
(40). When fed salmon steaks and salmon oil, providing 25-32 grams 
of omega-3 daily for four weeks, significant membrane composition 
changes occurred. The platelet phospholipids showed a fall in 
arachidonic acid from 28% to 20% and eicosapentaenoic and 
docosahexaenoic acids rose from barely detectable amounts to 7.4% 
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and 3. 7% respectively. The ratio of platelet eicosapentaenoic acid to 
arachidonic acid increased from 0.005 to 0.30. 
Once incorporation into the cell membrane has taken place, 
eicosapentaenoic acid and docosahexaenoic acids may be released with 
arachidonic acid from tissue phospholipids by phospholipases A2 or 
they may accumulate as free eicosapentaenoic acid or docosahexaenoic 
acid in metabolic pools (4). Eicosapentaenoic acid and 
docosahexaenoic acid compete with arachidonic acid for 
cyclooxygenase and may exclude arachidonic acid from the active 
binding site on the enzyme. The degree of inhibition of 
cyclooxygenase by eicosapentaenoic and docosahexaenoic acids is 
tissue and cell dependent as well as being influenced by the local 
concentrations of these fatty acids. 
Eicosapentaenoic acid can also compete in a direct fashion with 
arachidonic acid for metabolism via the lipoxygenase pathway (see 
diagram 8) ( 128). Leukotrienes B4 (LTB4) is a potent 
proinflamminatory, chemokinetic and chemotactic substance that can 
modulate inflammation, infection and immune function (4). 
Eicosapentaenoic acid can suppress LTB4 formation in certain cells by 
displacing arachidonic acid and by competing with it for lipoxygenase 
metabolism. In addition, the eicosapentaenoic acid derived mediator 
(LTB5) may exhibit reduced potency relative to those from arachidonic 
acid (LTB4), and may diminish the activity of LTB4 by competition for 
shared target cell receptors ( 15 7). 
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When eicosapentaenoic acid is substituted for arachidonic acid, 
cyclooxygenase converts eicosapentaenoic acid to hydroperoxides, 
PGG3 and PGH3 (see figure 8). These hydroperoxides formed from 
eicosapentaenoic acid, however, do not form as readily compared to 
those from arachidonic acid and thus eicosapentaenoic acid reduces 
cyclooxygenase activity in some cells (31). However, if peroxide 
concentrations increase, eicosapentaenoic acid may be more readily 
oxygenated to form trienoic prostaglandins. 
The eicosanoids derived from eicosapentaenoic acid have 
biological activities desirably distinct from their arachidonic acid-
derived analogs. In the vessel wall, eicosapentaenoic acid can be 
enzymatically converted into endoperoxides, PGG3 and PGH3, and 
hence into PGl3 which exerts a potent anti-aggregatory action on 
human platelets (154). Additionally, in the platelets, thromboxane A3, 
lacking in pro-aggregatory activity, can be derived from 
eicosapentaenoic acid. These anti-thrombotic effects have been 
proposed as a possible mechanism responsible for the low incidence 
of cardiovascular disease in the Eskimo population. 
Studies have indicated that eicosapentaenoic acid in human 
platelets is not pro-aggregatory like arachidonic acid, but may provide 
the substrate for an anti-aggregatory agent, prostaglandin of the "3" 
series (5,6,8, 79). One study demonstrated a significantly increased 
bleeding time in 21 Eskimo volunteers compared to Danish matched 
controls, 8.1 versus 4.8 minutes, respectively (39). A 
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FIGURE 8. Pathways of eicosapentaenoic acid metabolism. 
5-HPEPE: 5-hydroxyeicosapentaenoic acid; PGG3, 
PGH3: PG endoperoxides; PGI3; prostacyclin l3; 
LTB5: leukotriene B5; LTB5: leukotriene B5; .TxA3: 
thromboxane A3; TxB$ thromboxane B$ 
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substantial decrease in platelet aggregation was noted in another study 
as well. The plasma fatty acid patterns in this study demonstrated a 
higher ratio of omega-3 to omega-6 in Eskimos compared to the 
Danes, 1.38 and 0.10, respectively. The differences noted in the fatty 
acid composition between these two populations in conjunction with 
the increased bleeding times support the idea that there may be 
antithrombotic effects of omega-3 fatty acids. 
Additional platelet studies by Dyerberg et al found that 
eicosapentaenoic acid did not induce aggregation in human platelets 
even at concentrations five times greater than that of arachidonic acid 
(40). Speculation for this anti-aggregatory response was a 
displacement of arachidonic acid by eicosapentaenoic acid and direct 
utilization of eicosapentaenoic acid to synthesize a potent anti-
aggregatory agent PGI2. This effect reduces the amount of arachidonic 
acid available for the production of platelet thromboxane A2, a 
powerful pro-aggregatory agent. Manipulation of the balance between 
the arachidonic acid and eicosapentaenoic could alter the direction 
from a pro-aggregatory state to an anti-aggregatory environment. As 
such, enrichment of tissue lipids with eicosapentaenoic acid 
compared to arachidonic acid in the Eskimo population may explain 
the observed lower incidence of clinically apparent cardiovascular 
disease. 
In summary, production of eicosanoids is controlled at the level 
of the uptake, release and oxygenation of the precursor fatty acids as 
well as specific cell stimuli ( 128). The biosynthesis, mode of action 
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and pharmacological modulation of eicosanoid production have 
important biological implications. Understanding these complex 
biosynthetic pathways for the eicosanoid production and the interplay 
among substrates, such as modulation of dietary polyunsaturated fatty 
acids, may lend insight into the possible benefits of dietary 
manipulation and its effects on eicosanoid related disease states 
involved in vascular function. 
7 1 
IV. VASCULAR FUNCTION 
The potent and diverse effects of prostacyclin and thromboxane 
on platelet function has caused attention to be focused on their 
influence on human vasculature (159). Complex interactions between 
these constituents and components of the vessel wall are inolved in 
the pathogenesis of atherosclerotic disease and the subsequent 
thrombotic complications. Perturbation in the hemodynamic 
equilibrium maintained by these powerful chemical mediators may 
precipitate the development of these undesirable clinical events. On 
the basis of the ability of the prostaglandins to exert a myriad of 
biological activity, these substances are being considered as one of the 
most complicated groups of compounds to be encountered in medical 
research. 
The classic paper by Burr and Burr in 1930 introduced the 
concept of essential fatty acids which describe fatty acids which are 
necessary for normal physiological functions in animals and man and 
as such must be provided by diet due to the body's inability to insert 
double bonds at the appropriate sites ( 160). The derived essential 
fatty acids are all-cis C 20 polyallelic unsaturated fatty acids with 
three, four or five double bonds; dihomo-y-linolenic acid, (20:3w6); 
arachidonic acid, (20:4w6); and eicosapentaenoic acid, (20:5w3) 
(161). They are present in the phospholipids of the cell membranes 
of all mammalian tissues and are the substrates for the biosynthesis of 
prostaglandins of the "l ", "2", and "3" series respectively (see figure 
9). 
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FIGURE 9. Structures of the prostaglandins of the series 
1,2,and 3 and their fatty acid precusor. 
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Prostaglandin precursors lead to a group of several biochemically 
important products, called eicosanoids, which are extremely potent, 
ubiquitous compounds with a variety of diverse pharmacologic 
properties and significant medicinal potential. Evidence has indicated 
that eicosanoids are not circulating hormones, but rather locally active 
autacoids which are catabolized very near the place of formation ( 162). 
These powerful chemical mediators are not stored in the tissues but 
are formed upon stimulation (162). 
Platelets and their interaction with the vessel wall play an 
important role in the development of cardiovascular disease. Platelets 
maintain the integrity of the cardiovascular system by controlling the 
vascular permeability and inhibiting extravasation of blood or 
preventing localized hemorrhage into tissues (4). The endothelium . is 
involved in the exchange of materials either spontaneously or in 
response to atherosclerotic stimuli (42). The platelet-vessel wall 
interplay is of primary concern due to the formation of the coronary 
arterial thrombus which may lead to coronary ischemic syndromes 
such as acute myocardial infarction and sudden death (163). The 
biochemical process underlying the development of this thrombus may 
be affected by the dietary polyunsaturated fatty acids and resultant 
prostaglandin synthesis, thromboxane and prostacyclin. 
The discovery of TxA2 and PGI2 has led to an attractive 
hypothesis that certain aspects of cardiovascular disease may be 
explained on the basis of an imbalance of these compounds involved in 
the interaction of vessel wall and platelets ( 164). Such alterations in 
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prostaglandin production could result in increased platelet deposition 
and arterial thrombogenicity at atherosclerotic sites (165). The 
prostaglandins derived from the omega-6 precursor, arachidonic acid, 
are major regulators of the platelet-vessel wall interaction; TxA2 
formed in platelets is pro-aggregatory and a vasoconstrictor with PGI2 
formed in the vessel wall being anti-aggregatory and vasodilatory. 
Alterations in this metabolic pathway have been found to occur in the 
disease state and can be provoked by pharmacological intervention 
(9, 15,158,166,167). 
One study has demonstrated elevations in excretion of urinary 
TxA2 products in pathological conditions with increased platelet and 
vessel interactions such as unstable angina and myocardial infarctions. 
( 167). Prostacyclin synthesis was also found to be elevated in patients 
with atherosclerosis (166). It appears that, in conditions with 
increased platelet activity, TxA2 production far exceeds the synthesis 
of PGI2, thus favoring platelet aggregation (4). 
Pharmacological intervention may alter the synthesis of the 
powerful eicosanoid products of the long chain polyunsaturated fatty 
acids. Aspirin and other nonsteroidal antiinflammatory drugs 
(NSAIDs) block the synthesis of prostaglandins and TxA2 by inhibiting 
the cyclooxygenase enzyme (158). It appears that most NSAIDs act 
reversibly on cyclooxygenase whereas aspirin irreversibly acetylates 
the enzyme. A non-pharmacological way of modulating eicosanoid 
synthesis as well as a possible disease preventative measure, involves 
dietary manipulation of eicosanoid precursor fatty acids. 
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The data reported on the Eskimo: diet, bleeding times, platelet 
function and low incidence of heart disease led to the hypothesis that 
omega-3 fatty acids exert cardiovacular benefits via a favorable shift in 
eicosanoid metabolism towards an anti-thrombotic state (168). This 
condition has been attributed to triene prostaglandin production from 
eicosapentaenoic acid as well as a reduction in those from arachidonic 
acid. Studies have been conducted to determine the functional effects 
of a dietary shift from a diet high in omega -6 fatty acids to one high in 
omega-3 fatty acids. 
Results from studies on omega-3 fatty acids indicated that, in 
vitro, TxA3 production from eicosapentaenoic acid was less 
proaggregatory or inactive compared to TxA2 ( 169); in platelets 
eicosapentaenoic acid was a competitive inhibitor of TxA2 synthesis 
(170); PGl3 production occurred in human vasculature (171,172); and 
eicosapentaenioc acid does not inhibit PGI2 production in endothelial 
tissues (172,173). 
Human dietary supplementation studies have given investigators 
the opportunity to determine the effects of diets high in omega-3 
fatty acids (9, 15, 77,174). The measurement of prostaglandin urinary 
metabolites by gas chromatography mass spectrometry (GC/MS) has 
made it possible to quantify their biosynthesis in vivo. The non-
invasive GC/MS measurement of urinary metabolites avoids artifacts 
attributable to artificial activation of platelets during blood sampling 
and is now accepted as the best method available for assessing 
eicosanoid synthesis in vivo. 
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The ability to manipulate eicosanoid synthesis through dietary 
intervention has been documented in several clinical trials measuring 
urinary metabolites. Fischer and Weber demonstrated the formation of 
PGl3 in man following a diet rich in omega-3 fatty acids (77,174). 
Knapp et al (15) demonstrated a decrease in the TxA2 urinary 
metabolites in patients with severe atherosclerosis on high doses of 
fish oil (10g per day). Concurrently, accumulation of the dinor urinary 
metabolite of TxA3 occurred by the fourth week. A relationship 
between 'fxA3 and PGl3 metabolite excretion and dose and duration of 
omega-3 supplementation was also noted. If the omega-3 supplement 
was decreased a reduction in membrane eicosapentaenoic acid 
occurred which concided with a return toward baseline levels for TxA2 
production. Similarly, TxA2 decreased and TxA3 was detected in a 
group of mildly hypertensive patients receiving fish oil (9). Also PGI2 
and PGl3 increased in the group with a high dosage of fish oil while no 
reduction in total (PGI2 and PGl3) was seen. 
As demonstrated by these trials, a favorable shift in 
prostaglandin/thromboxane balance can be attained with 
supplementation of omega-3 fatty acids. However, the question 
remains as to what is the optimum dosage and what is the appropriate 
form of fish oil, both of which are important in the ability to achieve 
the desired responses. Is it realistic to expect to achieve these 
changes as a potential preventative measure for heart disease in a 
society who consumes 35-40% of the calories from fat with a major 
constituent being the omega-6 polyunsaturate, linoleic acid? Clinical 
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trials are needed to determine on the molecular level whether fish oil 
components can alter the progression of atherosclerosis and allow the 
development of realistic recommendations to either benefit the 
nutritional status of the general population or to treat individual 
patient groups as a medicinal agent. 
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SPECIFIC AIMS 
The goal of dietary intervention with omega-3 fatty acids in 
thrombosis and atherosclerosis is to reduce the incidence of 
cardiovascular disease. A potential surrogate marker reflecting the 
competition of eicosapentaenoic acid and arachidonic acid as 
substrates for the enzyme cyclooxygenase in the vasculature would be 
their conversion to PGl2 and PGl3, respectively. Therefore, measuring 
PGI2 and PGl3 metabolites could be used as an index of the 
incorporation and utilization of dietary EPA during . dietary 
manipulations. Concurrent with the generation of PGI2 and PGl3 , a 
reduction in the synthesis of TxA2 would occur with biosynthesis of 
TxA3 during dietary supplementation with eicosapentaenoic acid. 
Dietary manipulation of a low omega-6 high/omega-3 diet could 
possibly reduce the availability of linoleic acid and arachidonic acid as 
precursors for the synthesis of the pro-aggregatory eicosanoids thus 
favoring anti-aggregatory eicosanoids produced from omega-3 fatty 
acids. Most studies, however, do not control for the potential 
metabolic effects of total dietary fat on fatty acid incorporation and 
subsequent eicosanoid synthesis. Additionally, studies are limited on 
determining the most efficient means of supplying omega-3 fatty acids 
in the diet. Could a diet low in total fat, high in omega-3 fatty acids 
provide a more propitious environment for these desired outcomes? 
We have designed a study to evaluate these issues concerning 
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utilization of omega-3 fatty acids as a modulator of eicosanoids 
synthesis 
Specific aims are: 
1. To study the effect of dietary fat modulation, high fat or 
low fat diets with a standard fish oil supplementation on 
incorporation into plasma phospholipids; 
2. To study the effect of dietary fat modulation, high fat or 
low fat diets with a standard fish oil supplement on 
eicosanoid synthesis as determined by measurements of 
urinary prostacyclin metabolites; and, 
3. To study the effects of two different chemical forms of 
omega-3 fatty acids, ethyl ester and triglyceride, in 
conjunction with dietary fat modulation on phospholipid 
incorporation and subsequent eicosanoid synthesis in 
vivo. 
8 1 
MATERIALS AND METHODS 
MATERIALS AND METHODS 
This randomized, blinded, controlled study was conducted at 
the Nutrition Coordinating Center at the New England Deaconess 
Hospital, Harvard Medical School, Boston, MA. A parallel study design 
(see figure 10) was employed throughout the three phases. 
Experimental Design 
Subjects were recruited from among hospital employees, 
through advertising, and participant referral. Only adult males 
between the ages of 21 and 50 willing to participate for the full two 
months of the study were eligible. In addition, subjects were required 
to be free of all drugs and medication for the duration of the study; to 
be free to attend all clinic visits; to agree to comply with the dietary 
prescription and consumption of fish oil capsules; to submit to blood 
and urine testing; and to be capable of and willing to sign consent 
forms. 
Subjects were excluded if they demonstrated any acute or 
chronic disease; any unsuspected hematologic or coagulation 
disturbance found on the screen labs, such as bleeding time greater 
than ten minutes; any biochemical evidence of hepatic, renal, 
endocrine or cardiovascular disorder discovered on screening 
laboratory values; or an inability to consume fish oil or to comply with 
the dietary protocol. 
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FIGURE 10. Overview of study design. 
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Subjects taking any medication, especially aspirin, aspirin-
containing products, or nonsteroidal anti-inflammatory drugs (NSAID) 
were also excluded, as were those subjects who smoked. Subjects 
were made aware that NSAID would confound eicosanoid studies and 
would be detected by serum thromboxane. In addition subjects were 
told not to partake of exercise during day of urine collection, or 
consume alcohol the night prior to the urine collection or during the 
urine collection. Subjects were excluded if unable to understand or 
unwilling to sign the consent form. 
Phase 1 (screening 1 and 2) involved a two-week screening 
period to determine eligibility. At the initial screening visit, subjects 
underwent a history and a physical examination by the study physician; 
the research nutritionist answered any question regarding the 
protocol and instructed the subjects on how to complete a three-day 
food record, to collect a 24-hour urine sample, and to fast for 12-14 
hours prior to the next scheduled visit. 
At the second screening visit, all subjects underwent a 
chemistry profile and PT and PTT measurements for medical 
monitoring; plasma lipid profile; serum thromboxane determinations; 
and plasma fatty acid analysis. A baseline bleeding time was recorded, 
and a 24-hour urine sample was obtained to determine urinary 
prostaglandin metabolites as well as a urinary creatlnine level to assure 
a total urine collection. These laboratory measurements were used to 
determine eligibility and to provide baseline data for comparative 
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studies (see figure 11). Three-day food records were reviewed by the 
research nutritionist. At this time, each subject was placed on a run-
in diet based on the average American diet with 40% of their calories 
derived from fat, which would minimize alterations in plasma fatty 
acids and enable the investigator to assess the ability of the subject to 
comply with the dietary protocol. This also allowed for a standardized 
fat intake of the study population. 
During Phase 2 (run-in 1 and 2), a two-week "run-in" period, 
subjects followed the prescribed diet. At the end of the second visit 
(run-in 2) data were collected on blood chemistry, plasma lipids, 
serum thromboxanes, PT and P1T times, and plasma fatty acids; a 24-
hour urine sample was obtained to determine urinary prostaglandin 
metabolites and urinary creatinine level. In addition, each subject was 
randomized at the end of the second run-in week: eligible subjects 
selected a sealed envelope to determine to which of the four dietary 
intervention groups they had been assigned: 
1. Low-fat (20% of calories) diet plus 8 grams of omega-3 
fatty acids fish oil in capsule form, with approximately 
4.8 grams from EPA, given as triglycerides 
2. Low-fat (20% of calories) diet plus 8 grams of omega-3 
fatty acids fish oil in capsule form, with approximately 
4.8 grams from EPA, given as ethyl esters 
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FIGURE 11. Study data collection points. 
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s s R R w w w w 
1 2 1 2 1 2 3 4 
------------------
----- -----
History/Physical X X 
------------------
----- -----
Informed Consent X 
------------------
----- -----
BLOOD 
------------------
----- -----
Lipid Profile X X X X 
------------------
----- -----
Bleeding Time X X X 
------------------
----- -----
FA Analysis X X X X 
------------------
----- -----
Serum TxB2 X X X X 
Serum TxB3 
----------------
---- ---- --- ---- -----PT and PTT X X 
------------------
----- -----URINE 
------------------
-----
Metabolic Analysis X X X X 
------------------
----- -----
DIET 
------------------
----- -----
3 Day Food Recall X X X X 
------------------
-----
S = Screening visit 
R=Run in period 
W=Week 
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3. High-fat (40% of calories) plus 8 grams of omega-3 fatty 
acids fish oil in capsule form, with approximately 4.8 
grams from EPA, given as triglycerides 
4. High-fat (40% of calories) plus 8 grams of omega-3 fatty 
acids fish oil in capsule form, with approximately 4.8 
grams from EPA, given as ethyl esters 
The triglyceride groups consumed 10 capsules per day, with the 
ethyl ester groups consuming 12 capsules per day. The triglyceride 
form of the fish oil capsules was similar in appearance to the ethyl 
ester form. The triglyceride was kindly provided by Advanced 
Nutritional Technology, Elizabeth, NJ (Super EPA 1200). The 
triglyceride groups were supplemented with 10 capsules per day and 
instructed to consume capsules with breakfast, lunch and dinner (3,3 
and 4 capsules respectively). Daily supplementation provided 
approximately 4.8 gram from EPA and 3.0 grams from DHA. The ethyl 
ester was provided by the National Institutes of Health and the 
National Oceanic and Atmospheric Administration, National Marine 
Fisheries Service, Charleston, SC. Subjects were given the same 
instructions for incorporation of capsules into the diet as the 
triglyceride groups with the exception that the ethyl ester groups had 
to consume 12 capsules per day to achieve the same amount of EPA. 
Subjects took 4 capsules with each of the three meals per day which 
provided approximately 4.8 grams of EPA and 2.8 grams of DHA. 
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Phase 3 consisted of a four-week active intervention period 
during which subjects followed their dietary and capsule 
supplementation prescription. Each Phase 3 visit ( Weeks 1, 3 and 4) 
included measurement of body weight, determination of adverse 
experiences, and counting and distribution of capsules. Data were 
collected on blood chemistry,plasma lipids, serum thromboxanes, and 
plasma fatty acids; a 24-hour urine sample was obtained to determine 
urinary prostaglandin metabolites and urinary creatinine level. The 
research nutritionist evaluated the three-day food records and the fat-
gram score sheets with the subjects and made necessary 
recommendations to maintain the desired level of fat intake. 
Verification of compliance was assessed at each visit by recorded 
pill count, by interview, and by questionnaire. In addition, a plasma 
fatty acid analysis was conducted to monitor compliance to fish oil 
supplementation, and serum thromboxane was measured to ensure 
abstinence from aspirin, aspirin preparation or anti-inflammatory 
drugs. 
Dietary Intervention 
Each subject was instructed by the research nutritionist to 
follow each diet (Run-in and Active Intervention) based on the fat-
gram counting method. The dietary goals were described to the 
subjects in terms of fat grams rather than caloric content. Each 
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subject was given a required number of fat grams to consume per day 
to achieve the required amount of dietary fat. In addition, both the 
usual American diet (high-fat) and the low-fat diet consumed by the 
subjects were based on the food-exchange plan; subjects were 
encouraged to follow the exchange plan in conjunction with the fat-
gram counting protocol. 
Caloric intake for each participant was determined by the 
Harris-Benedict formula (175) adjusted for activity and caloric intake 
as calculated from the baseline three-day food record. Each subject 
was given a diet adequate in calories to maintain present body weight. 
If weight fluctuated by more than three to four pounds, the caloric 
intake was adjusted to meet the needs of the individual to maintain or 
to achieve entry weight. Subjects were provided with education 
materials to aid in dietary compliance, including sample menus and 
food preparation tips, fat-gram counting books, fat-gram score sheets, 
a food exchange list, and instructions for food record keeping. 
Careful dietary instruction was provided for both groups to 
ensure that fat consumption is maintained at the desired levels (20% 
and 40% of total calories) with 20% of calories from protein and 60% 
from carbohydrates for the low fat group and 20% derived from 
protein and 40% derived from carbohydrates for the high fat group. 
In addition, the low fat group was to achieve a dietary omega-3 to 
omega-6 ratio of one. Dietary compliance was evaluated by the 
research nutritionist at each clinic visit based on a three-day food 
record and fat-gram score; a non analyzed compliance questionnaire 
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was also completed by each participant. Each food record and fat 
gram score was carefully reviewed with the subject to determine 
accuracy of the food documentation, portion size, and preparation, and 
to clarify nutrient information when necessary. At this time, each 
subject was provided with the required amount of fish oil capsules to 
last until the next visit: on run-in one and week three, subjects 
r~ceived either 70 triglyceride capsules or 84 ethyl ester capsules, 
and on Week 1 received either 140 or 168 capsules, respectively. 
Documentation of fish oil consumption was determined by pill count 
based on bottles returned at each clinic visit, which was recorded on 
the fish-oil capsule log form. 
CLINICAL AND LABORATORY MEASUREMENTS 
All subjects were instructed to fast, including exclusion of fish 
oil capsules, for 12-14 hours prior to laboratory measurements. The 
laboratory measurements collected at baseline were also collected at 
run-in 2 and weeks 1 and 4, with the exception of a bleeding time, 
which was not conducted on run-in 2. For analysis purposes, run-in 2 
data were analyzed as the baseline measurement for laboratory and 
urine measurements and compared with week one and week four .. 
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Dietary Analysis 
Dietary intake was assessed by the research nutritionist with the 
subjects to ensure completeness and accuracy. Food records were 
analyzed by use of the Food Processor II Nutrition and Diet Analysis 
System from ESHA Research, Salem, OR. This system, lists over 2400 
foods and 30 nutrients, is a software package based on the latest USDA 
data plus over 400 additional sources; content of w-3 fatty acids were 
added to the data analysis according to the USDA Provisional Table on 
the Content of w-3 Fatty Acids and Other Fat Components in Selected 
Foods (176). 
Bleeding Times 
Bleeding time was measured by use of the template bleeding 
device (Oregon Tech, Durham, NC) (177). A blood pressure cuff was 
placed over the subject's forearm, and the pressure increased to 40 
mm Hg. A space was found below the cuff (three to four finger 
breadths from the center of the forearm), and the device triggered, 
making a small cut into the forearm. Every 30 seconds, the site was 
blotted lightly with filter paper, and the time required to stop 
bleeding was noted. The lab technician was blinded as to the the 
subjects consumption of fish oil. 
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Lipid Profile 
Total cholesterol, triglycerides, and HDL-C were measured by 
automated methods employed by Smith Kline Bioscience Laboratories 
(King of Prussia, PA). The total cholesterol and triglycerides were 
measured by using enzymatic methods. HDL-C was determined by the 
heparin-Mn2+ precipitation method. LDL was determined by 
calculation (LDL=T Chol - HDL - Tg/5). 
Measurements of Urinary Prostacyclin Metabolites 
Urinary 2,3 dinor-6-keto-PGF1a, a major metabolite of PGI2, and 
its ~17 analogue derived from PGI3 were measured by a stable isotope 
dilution method employing tetradeuterated 2,3 dinor-6-keto-PGF1a 
(a generous gift of the Upjohn Company). After alkaline equilibration 
of the lactone forms of the endogenous compound and the deuterated 
standard, the urine was acidified, applied to a solid-phase extraction 
column preconditioned with methanol and then water, and the 
prostanoids eluted with methylene chloride (178). After evaporation 
of the ethyl acetate under N2, the free acids were derivatized to their 
methoxime derivatives by treatment overnight with methoxylamine 
HCI (Aldrich Chemical Co., Milwaukee, WI) in pyridine (1:9 v/v) at 
room temperature. After evaporating the pyridine under N2, the 
pentafluorobenzyl (PFB) esters were then formed with a-bromo 
pentaflurotoluene (Aldrich) in acetonitrile 20 ul (1 :9 v /v), with 20 ul 
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diisopropylamine as reported earlier ( 1 79). The derivatives usually 
were purified by thin-layer chromatography (TLC) on silica gel G, using 
2% methanol in ethyl acetate as developing solvent. After being 
extracted from the silica with ethyl acetate, they were then treated 
with (bis)trimethylsilyl-trifluoroacetamide (Supelco, Inc., Bellefonte, 
PA) at room temperature overnight in pyridine (1: 1 v /v) to form the 
trimethylsilyl ethers. Samples were analyzed by gas 
chromatography /mass spectrometry in the negative ion-chemical 
ionization (NICI) mode with methane as reagent gas on Nermag 10-
l0C instrument under condition described below, using capillary gas 
chromatography columns (SPB-1, Supelco). Selected ion monitoring 
(SIM) was employed, monitoring m/z 584, 586, and 590 for the 
methoxime-(tris) TMS ether-PFB esters of ~ 17-2,3-dinor-6-keto-
PGFla 2,3 dinor-6-keto-PGF1a, and its tetradeuderated internal 
' 
standard, respectively. 
Measurement of Serum Thromboxanes 
Venous blood was collected into glass tubes and allowed to clot 
at 37° C for 45 min. The clot was removed by centrifugation and the 
serum frozen at -20° C until analysis. Serum thromboxane B2 and 
thromboxane B3 were measured by gas chromatography-negative-ion 
chemical ionization-mass spectrometry. Because of the large amounts 
of thromboxane present in serum, 25 µl was sufficient for analysis. 
After 2 ng of the tetradeuterated thromboxane B2 (Biomol; Newton, 
MA) was added, the sample was acidified to pH 3.0 with dilute HCl and 
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extracted into ethyl acetate. After evaporation of ethyl acetate under 
N 2, thromboxanes were derivatized to their methoximes and 
pentafluorobenzyl esters as described above, and subsequently purified 
by thin-layer chromatography. A final derivatization, to the 
trimethylsilyl ether, allowed quantitation by selected ion monitoring at 
m/z 618 for the tetradeuterated internal standard, m/z 614 for 
thromboxane B2 and m/z 612 for thromboxane B3 (181). 
Gas Chromatography-Mass Spectometry Conditions 
GC-MS is carried out on a Nermag Rl0l0C quadrupole mass 
spectrometer (Delsi Instruments, Dallas TX) interfaced with a Varian 
Vista gas chromatograph (Varian, Palo Alto) (180). Data reduction and 
analysis are carried out using Nermag SIDAR software. A 10 m SPB-1 
fused silica column (0.25 mm id; 0.25 µm coating thickness, Supelco, 
Bellefonte, PA) is passed through the transfer line from the gas 
chromatograph until the end is just inside the ion source. The glass 
inserts for the gas chromatograph injector are cleaned with chromic 
acid, silanized with dimethyl-dichlorosilane in toluene ( 1 :9 v /v) for 30 
min., deactivated in methanol for 10 min., washed with methanol and 
dried at 100°. A clean glass liner is inserted in the injector 
immediately prior to analysis and the temperature maintained at 250°. 
Helium (Alphagaz, San Francisco, CA; high-purity grade), d1:"ied and 
oxygen- free (gas purifier, Supelco), is used as the carrier gas at a flow 
rate of 1 ml/min (head pressure 10 psi). The source and transfer 
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lines of the mass spectrometer are maintained at 250° and 260°, 
respectively. The conversion dynode is set at a +5 kV and the 
multiplier at 2.4 kV. 
Injections are made in the splitless mode. Flow of helium 
through the sweep and split valve is stopped for 0.2 min. prior to 
injection. It is opened 0.8 min later and the oven temperature 
program initiated from 190 to 310 ° at 20°/min. The column is held 
at 310° for 15 min. at the end of the chromatographic run to remove 
potential interfering substances. The retention time for 2,3 dinor-6-
keto-PGF1cr MO-(tris)TMS-PFB is approximately 4.2 min. and that of 
TxB2-MO-(Tris)TMS-PFB is 5.5 min. under these conditions. 
Selected-ion monitoring is carried out by monitoring the appropriate 
ions as described above for PGI-M and TxB. A calibration curve is 
prepared by analyzing the extracted standards and plotting the relative 
peak heights (or peak areas) of m/z 614 to m/z 618 (for TxB and its 
deuterated standard) against concentration. The biological samples 
are then analyzed. Great care is taken to avoid cross-contamination of 
samples with the injection syringe. "Memory effects" can be 
minimized by flushing the syringe first with methanol and then with 
ethyl acetate. The relative peak heights (or peak areas) of m/z 614 to 
m/z 618 (forTxB) are determined for the biological samples. 
Concentrations of TxB2 and TxB3 are then calculated by interpolation 
from the standard curve, and a similar procedure is followed for PGI-
M's. 
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Analysis of Fasting Plasma Phospholipid Fatty Acids 
The organic phase from Folch extracts of plasma was applied to 
silica-gel G thin-layer plates (Analtech, Newark, Del.), and the 
phospholipids were separated, using petroleum ether: diethyl 
ether:acetic acid (170:30:2) as developing solvent (182). Fatty acid 
methyl esters were prepared with BF3-methanol (183) and were 
analyzed with a gas chromatograph equipped with a flame ionization 
detector (Varian 2100, Varian, Palo Alto, CA) on a 2-m column 
(internal diameter, 2mm) packed with 10 percent SP 2340 on 
Supelcoport (Supelco, Bellefonte, PA). Peaks were located by 
comparison with retention times of known standards (Nu-Chek Prep; 
Elysian, MN). 
Statistical Analysis 
The data from nutrient intake and lipids and bleeding times 
were analyzed by use of Wilcoxon's signed-ranks test for paired 
comparison with control values and the Kruskall and Wallis one way 
analysis of variance. Data on urinary metabolites, phospholipids and 
serum thromboxanes were subjected to analysis of variance according 
to the method of Friedman and changes in group means were 
compared by the method of Dunn. These types of nonparametric 
measurement were used to avoid assumptions about distribution of 
variables involved (184). Values are expressed as the mean± SEM. 
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RESULTS 
RESULTS 
Demographics 
Of the 25 subjects randomized into the study, 24 completed the 
protocol and have been included in the analyses. One subject had to 
discontinue the study due to an increase in bilirubin levels after one 
week of fish oil supplementation, and a follow-up without the fish oil 
showed a return to his baseline levels. 
Table 4 presents age, body weight and body mass indexes (BMI) 
at baseline and week 4. There were no significant effects of the 
dietary intake (low fat or high fat) on body weight or BMI over the four 
week intervention period for any of the four groups. Comparison at 
baseline and week 4 among the four groups for body weight and BMI 
indicated statistically significant differences. The high fat ethyl ester 
group (HFEE) weighed significantly less and had a significantly smaller 
BMI (P<0.05) compared to the low fat triglyceride group (LFTG), low 
fat ethyl ester group (LFEE) and the high fat triglyceride group 
(HFTG) . 
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Dietary Analyses 
Table 5 shows the energy and nutrient intakes at baseline and 
end of active intervention, week 4. No significant differences were 
found among the four groups at baseline and at four weeks for calories, 
carbohydrate or protein. All subjects maintained their entry level 
weights. There were no statistically significant differences in 
percentage of calories derived from fat, total fat grams and grams of 
polyunsaturated fatty acids (PUFA), monounsaturated fatty acids 
(MONO) or saturated fatty acids (SFA) among the four groups at 
baseline. Also, no differences were noted for baseline intake of omega-
3 or omega-6 fatty acids or the ratio of omega-3 to omega-6 among the 
four groups. 
Significant changes occurred both within the low fat groups and 
between the low fat groups compared to the high fat groups following 
the four week intervention period in percent calories from fat, total fat 
grams, PUFA, MONO and SFA fatty acids. At week four there was a 
significant reduction (P~0.05) in percent calories from fat, total fat 
grams, polyunsaturated, monounsaturated and saturated fats in the 
LFEE and LITG groups compared to the HFEE and HITG groups. A 
significant reduction (P~0.01) was noted in percent of calories derived 
from fat comparing baseline to week four for both groups, (LFEE 41 o/o 
and LITG 46%). 
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Total fat grams were significantly reduced (P~0.05) between 
baseline and week 4 for both LFEE and LFTG, 64% and 60%, 
respectively. Significant reductions were also found for PUFA, MONO, 
and SFA fatty acids between baseline and week four for the low fat 
groups. No significant changes were found between baseline and week 
four for any of the above intakes of total fat grams, PUFA, MONO, or 
SFA in either the HFTG or HFEE groups. 
Further dietary analyses of the intake of omega-3 and omega-6 
fatty acids and the ratio of omega-3 to omega-6 demonstrated no 
significant differences at baseline among the four groups. A significant 
increase in omega-3 fatty acids (P~0.01) was found between baseline 
and week four for all four groups during the active intervention period. 
Intake of omega-6 fatty acids was significantly reduced (P~0. 05) 
at week four for the low fat groups, LFTG and LFEE, compared to the 
high fat groups HFTG, and HFEE. Comparing baseline levels with 
week four levels, the statistical analysis revealed a significant (P~0.01) 
reduction in omega-6 fatty acids for the LFTG and LFEE, (60% and 
84%, respectively) The ratio of omega-3 to omega-6 was significantly 
(P~0.05) increased when comparing the baseline levels with week 1 
and week 4 for all four groups. Comparing week one and week four 
the ratio in LFTG and LFEE groups showed a significant increase 
(P~0.05) compared to the HFTG and HFEE groups (Table 6). 
Compliance with fish oil supplementation as documented by 
capsule count was 97% for the LFTG, 93% for the HFTG, 94% for the 
LFEE and 95% for the HFEE. 
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Lipid Analyses 
There were no statistically significant differences in any of the 
following lipid parameters measured except for triglycerides; total 
cholesterol, low density lipoproteins (LDL), high density lipoproteins 
(HDL), either in comparing baseline with week four within the groups 
or a comparison among the four groups at baseline or week four (Table 
7). However, the greatest total cholesterol reduction was found in the 
LFEE group, 14%, compared to 6.8%, 2.1% and 2.8% for the LITG, 
HFTG and HFEE, respectively. LDL was noted to decrease more in the 
LFEE group, 18%, compared to 6.2% in the LITG. In contrast LDL 
increased in both the high fat groups the greatest increase in the 
HITG group, 20% with a small increase in the HFEE group, 1.1 %. 
Triglyceride levels decreased significantly (P~0.05) for all four 
groups following one week of fish oil supplementation with the largest 
decrease found in the HITG group. Week four levels however 
appeared to start to increase when compared to week 1 
measurements in all groups except for the HFEE which was 
significantly lower (Table 8). 
BLeeding Time 
Template bleeding times were not found to be significantly 
different among the , four groups for data collection points at baseline, 
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week one or week four. The LFTG group was the only group to 
demonstrate a significantly (P~0.05) prolonged bleeding time when 
comparing baseline with week four (Table 9). There seemed to be a 
trend towards a decrease in bleeding time from baseline to week one 
for the LFTG, HFTG and HFEE, (8%, 4%, and 16%, respectively). A 
slight increase ( 17%) occurred in the LFEE following the one week of 
dietary intervention and fish oil supplementation. Only small 
decreases in bleeding times were noted at week four for HFTG and 
IFEE. 
When evaluating individual changes within each group, the LFTG 
had one subject increase (from 4 to 6 min), whereas the other 
subjects' bleeding times remained the same or decreased by week 1. 
By week four, four of the six subjects showed an increase in bleeding 
time. In the HFTG group three of the individuals showed an increase 
in bleeding time at week one. Four of the subjects in the LFEE group 
had an increase in bleeding time at week one, with three of the them 
maintaining the increase or continuing to increase by week four. The 
HFEE had two patients increase after one week of supplementation 
and maintained that increase by week four, two other subjects had an 
increase from week one. 
Plasma Phospholipid Analyses 
Phospholipid fatty acid patterns determined by percent weight 
are depicted in Table 10. Compared to baseline values, statistically 
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significant increases (P~0.05) were found for eicosapentaenoic fatty 
acids (EPA, 20: 5) following one week of dietary intervention plus fish 
oil supplementation for all four groups. All four groups, LFTG, HFTG, 
LFEE, and HFEE, had similar increases amounts of EPA in the 
phospholipid class, 86%, 92%, 90% and 93%, respectively. 
Incorporation of docosahexaenoic fatty acids (DHA, 22:6) was also 
significant (P~0.05) for the HFEE group following week one of 
intervention. A statistical significance (P~0.05) was found for 
incorporation of EPA and DHA at week four for all four groups 
compared to the baseline levels. No significant differences were found 
among the groups at weeks one or four for incorporation of either EPA 
orDHA. 
Incorporation of the EPA appeared to be influenced by the form 
of omega-3 fatty acid. Of the low fat groups with similar baseline 
values for EPA, there was a higher incorporation of EPA in the low fat 
ethyl ester group compared to the low fat triglyceride group (7.0% vs 
3.5% week one and 9. 7% vs 4. 7% week four) despite a higher ratio of 
dietary omega-3 to omega-6 in the LFTG group compared to the LFEE 
group (1.15 vs 0.94, week 1 and 1.16 vs 0.90, week 4). 
A statistically significant reduction (P~0.05) was found for 
linoleic acid (18:2) in the LFEE and HFEE groups at the end of the 
four week period while the HFTG group showed a significant 
reduction (P~0.05) in arachidonic acid (AA, 20:4) by week four. 
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Serum 1'xB2 and SerumTxB3 
Serum thromboxane B2 (Tx:B2) production decreased in all four 
groups compared to baseline values (Table 11). Statistically significant 
reductions (P~0.05) occurred in three of the four groups, LFTG, HFEE, 
and HFTG, with mean decreases of, 40%, 30% and 23% respectively. 
The LFTG group had a significant greater decline than the other 
groups (P~0.05) at week one. Measurements for TxB2 at week four 
compared to baseline showed statistically significant similar 
reductions (P~0.05) for all four groups; LFTG,41%; HFTG, 46%; LFEE, 
48% and HFEE, 50%. No significant differences were noted for 
comparisons among measurements at week four for TxB2. 
In contrast to a reduced serum TxB2 production, serum TxB3 
production increased significantly (P~0.05) for all four groups by 
weeks one and four (Table 11). The HFTG group showed the largest 
increase in TxB3 at week one and week four. 
Eicosanoid Synthesis In Vivo 
The excretion of 2,3-dinor-6-keto-prostaglandin F1 a (PG 12-M) 
and ~ 17~ 2,3-dinor-6-keto-prostaglandin Fla (PGI3-M) were not 
different among the treatment groups at the baseline period (Table 
12). However, there was a significant increase (P~0.05) for both the 
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LFTG and HFTG groups, (23% and 21%), respectively, for PGI2-M 
from baseline. The small increases for PGI2-M in the low fat and high 
fat ethyl ester groups were not statistically significant. 
All subjects produced significant amounts of PGI3- M 
following dietary intervention and fish oil supplementation (Table 12). 
The HFTG group mean production of PGI3-M was significantly higher 
(P~0.05) compared to the LITG, LFEE, and HFEE groups at week one 
(27.9 fold increase vs 16.3, 15.2, and 15.3 fold, respectively). At week 
four, PGI3-M values in the HFTG group were reduced to levels not 
significantly different from amounts excreted in the LFTG, LFEE and 
HFEE groups. 
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TABLE 4 
DEMOGRAPI-IlCS OF STUDY SUBJECTS IN TIIE FOUR GROUPS: AGE, BODY WEIGHT AND BODY 
MASS INDEX (BMI) AT BASELINE (BL) AND WEEK 4 (WK4)* 
LFTG HFTG LFEE HFEE 
BL WK4 BL WK4 BL WK4 BL WK4 
Age 30 --- 32 --- 33 --- 34 ---
(±1.6) (±2.3) (±2.0) (±3.0) 
Body weight 83.92 82.95 79.18 79.93 79.23 78.42 68.67t 68.47 t 
(±2.6) (±2.6) (±3.4) (±3.5) (±2.9) (±3.0) (±2.6) (±2.7) 
BMI 24.82 24.55 24.87 25.08 23.62 23.82 22.43t 22.18 t 
(±0.4) (±0.4) (±0.4) (±0.4) (±0.6) (±0.7) (±0.9) (±0.9) 
•Mean± SEM. n=6 in each group. LITG (low fat triglyceride), HITG (high fat triglyceride). LFEE ( low fat ethyl ester), HFEE 
(high fat ethyl ester). 
t Significantly different from other three groups. P~0.05 . 
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TABLES 
DAILY NU1RIENT INTAKES FOR EACH OF TI-IE FOUR GROUPS FOR BASELINE (BL)AND WEEK 4 (WK4)BASED ON 
. TI-IREE DAY FOOD RECORDS• 
lFTG IIFTG U'EE IIFEE 
BL WK4 BL WK4 BL WK4 BL 
Total energy (kcal) 2563 165lt 2624 2634 3177 2216t 2659 
(±218.6) (±154.6) (±216.5) (±293.7) (±269.2) (±265.9) (±185.n 
Percent calories 45.83 58.33 43.66 44.67 48.83 61.5 45.17 
from CHO (±2.5) (±4.5) (±3.2) (±2.1) (±3.6) (±3.1) (±3.1) 
Percent calories 16.33 21.66 18 17.83 16.5 18.17 16.33 
from protein (±1.0) (±2.6) (±1.4) (±0.9) (±1.5) (±1.6) (±1.3) 
Percent calories 37.66 20.17tt § 38.33 37.3 34.83 19.83tt § 38.67 
from fat (±2.3) c±2.n (±2.0) (±1. 7) (±3.1) (±1.6) (±2.7) 
Total fat (g) 105 36.8t § 110.3 109.88 122 47.93t § 111.17 
(±8.3) (±5.0) (±5.1) (±10.0) (±11.0) (±4.1) (±7.4) 
Polyunsaturated 23.14 9.29t § 23.52 22.73 24.58 10.5lt § 25.53 
fats (g) (±3.4) (±1.l) (±3.0) (±2.8) (±5.1) (±0.8) (±3.0) 
Monounsaturated 39.3 12.76t § 39.82 38.81 40.26 15.35t § 40.25 
fats (g) (±2.2) (±2.2) (±1.0) (±2.4) (±4.2) (±1.1) (±3.1) 
Saturated fats (g) 33.03 11.54 t § 38.25 39.97 44.52 16.69t § 36.53 
(±3.9) (±1.9) (±2.1) (±5.1) (±4.9) (±2.3) (±3.1) 
Omega-3 (g) 2.01 8.46 tt 1.21 8.72tt l.ll 8.5tt 1.37 
(±0.5) (±0.1) (±0.3) (±0.3) (±0.28) (±0.19) (±0.3) 
Omega-6 (g) 21.13 8.38 tt § 22.36 21.52 23.40 9.71 tt § 24.22 
(±3.0) (±1.1) (±2.9) (±2.6) (±5.0) (±0.7) (±2.8) 
Ratio n-3 to n-6 0.1 l.16t § 0.17 0.43t 0.05 0.9t § 0.06 
(±0.02) (±0.2) (±0.1) (±0.06) (±0.02) (±0.05) (±0.01) 
•Mean± SEM, n=6 in each group. LFfG (low fat triglyceride), HFTG (high fat triglyceride), LFEE (low fat ethyl 
ester), HFEE (high fat ethyl ester). 
t Significantly different from baseline values, P ~ 0.05. tt Significantly different from baseline values, P ~ 
0.01. § Stgntflcantly different from values in other groups at week four, P ~ 0.05. 
WK4 
2480 
(±213.0) 
41.33 
(±2.0) 
16.83 
(±1.5) 
42.0 
(±1.3) 
115.03 
(±6.9) 
21.43 
(±2.9) 
43.88 
(±2.9) 
37.72 
(±6.7) 
8.88tt 
(±0.2) 
20.38 
(±2.9) 
0.52t 
(±0.1) 
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TABLE 6 
COMPARISON OF DIETARY OMEGA-3:0MEGA-6 RATIO: BASELINE (BL), WEEK ONE (WKl) AND WEEK 
FOUR (WK4) FOR THE FOUR GROUPS* 
LFTG HFTG LFEE HFEE 
BL WKl WK4 BL WKl WK4 BL WKl WK4 BL WKl WK4 
Omega-3:omega-6 0.09 1.15 t§ 1.16 t§ 0.18 0.45t 0.43t 0.06 0.94 t§ 0.9 t§ 0.05 0.4t 0.5t 
Ratx> ±0.02 ±0.27 ±0.2 ±0.06 ±0.06 ±0.06 ±0.02 ±0.16 ±0.05 ±0.008 ±0.02 ±0.1 
•Mean± SEM, n=6 in each group. LFTG (low fat triglyceride), HFTG (high fat triglyceride), LFEE (low fat ethyl ester), HFEE (high 
fat ethyl ester). 
t Significantly different from baseline. P~0.05. 
§ Significantly different from other three groups, P~0.05. 
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TABLE 7 
COMPARISON OF TOT AL CHOLESTEROL, LOW DENSITY LIPOPROTEINS (LDL), AND HIGH DENSITY 
LIPOPROTEINS (HDL) AT BASELINE (BL) AND WEEK FOUR (WK4) FOR THE FOUR INTERVENTION 
GROUPS* 
IFl'G HFTG LFEE HFEE 
BL WK4 BL WK4 BL WK4 BL WK4 
Cholesterol (mg/ di) 171.5 159.7 191.8 187.7 208.2 177.5 184 178.8 
(±15.9) (±13.1) (±20.0) (±15.4) (±19.2) (±18.6) (±17.6) (±16. 7) 
LDL (mg/di) 104 97.6 127 158.4 143.5 117.7 116.2 117.5 
(±14.7) (±11.9) (±19.3) (±14.8) (±18.6) (±15. 7) (±16.6) (±16.5) 
HDL (mg/di) 51.0 48.7 48.3 49.2 44.8 43.3 51.8 50.5 
(±3.0) (±4.0) (±4.8) (±3.9) (±1.6) (±2.4) (±3.7) (±6.9) 
*Mean± SEM, n=6 in each group. LITG (low fat triglyceride), HITG (high fat trtglycertde), LFEE (low fat ethyl ester), HFEE 
(high fat ethyl ester) 
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TABLE 8 
COMPARISON OF TRIGLYCERIDE LEVELS: BASELINE (BL), AND ONE (WKl) AND FOUR WEEKS (WK4) 
FOR TIIE FOUR GROUPS* 
LFTG HFTG LFEE IIFEE 
BL WKl WK4 BL WKl WK4 BL WKl WK4 BL WKl WK4 
Triglycerides 83 56.7 t 69.3 84.8 55.2 t 64.7 101 73.8 t 85.5 87.2 61.3t 56.7t 
±13.2 ±7.3 ±15.3 ±14.9 ±6.8 ±16.2 ±10.4 ±16.1 ±25.6 ±17.5 ±12.4 ±11.1 
•Mean± SEM, n=6 in each group. LFTG (low fat triglyceride). HFTG (high fat triglyceride). LFEE (low fat ethyl ester). HFEE (high 
fat ethyl ester). 
t Significantly different from baseline. P s 0.05. 
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TABLE 9 
COMPARISON OF BLEEDING TIMES: BASELINE (BL), WEEK ONE (WKl) ANDWEEK FOUR (WK4) FOR 
1HE FOUR GROUPS* 
LFTG HFTG LFEE HFEE 
BL WKI WK.4 BL WK.I WK.4 BL WK.I WK4 BL WKI WK4 
Bleeding time (min.) 5 4.6 6.3t 5 4.8 4.2 4 4.8 4.7 5 4.5 4.8 
±0.6 ±0.5 ±0.8 ±0.7 ±0.9 ±0.3 ±0.5 ±0.4 ±0.4 ±0.3 ±0.6 ±0.5 
•Mean± SEM, n=6 in each group. LFTG (low fat triglyceride), HFTG (high fat triglyceride). LFEE (low fat ethyl ester), HFEE 
(high fat ethyl ester) 
t Significantly different from baseline, P ~ 0 .05. 
TABLE 10 
PERCENf OF TOTAL FATIY ACIDS BASED ON PERCENT WEIGHT IN PHOSOPHOLIPIDS FOR 
TiiE FOUR GROUPS AT BASELINE (BL) WEEK ONE (WKl) AND WEEK FOUR (WK4) • 
16:0 18: 0 18: 1 18:2 20:4 20: 5 22:6 
BL 
LF/fG 30.8 12.2 14.7 26.4 11.4 0.5 3.1 
(±8.4) (±3.0) (±2.3) (±9.0) (±3.9) (±0.3) (±1.0) 
HF/TG 32.6 13.4 13.8 25.5 11.8 0.5 2.8 
(±2.7) (±2.2) (±2.8) (±4.4) (±3.8) (±0.6) (±1.3) 
LF/EE 30.4 10.7 16.4 24.5 12.3 0.7 3.9 
(±4.2) (±3.1) (±10.7) (±7.1) (±3.5) (±0.3) (±1.3) 
HF/EE 29.7 13.1 13.2 28.5 10.6 0.6 2.9 
(±2.1) (±2.7) (±1.2) (±3.5) (±2.3) (±0.2) (±0.8) 
WK.I 
LF/TG 32.9 13.7 12.6 20.7 12.7 3.5t 3.3 
(±2.9) (±2.6) (±3.4) (±2.3) (±2.6) (±2.4) (±1.4) 
HF/TG 30.8 12.8 11.9 23.6 10.0 6.4t 4.4 
(±2.2) (±3.8) (±1.0) (±2.2) (±1.8) (±3.5) (±1.4) 
LF/EE 32 .5 13.3 12.0 22.3 12.3 7.0t 4.7 
(±3.4) (±3.4) (±1.6) (±2.5) (±1. 7) (±3.4) (±0.8) 
HF/EE 27.9 12.3 11.6 24.3 13.7 9.1 t 4.8t 
(±3.0) (±3.8) (±1.9) (±7.6) (±2.0) (±5.6) (±1.7) 
WK4 
LF/TG 32.4 13.9 12.4 21.6 9.9 4.7t 4.7t 
(±3.6) (±3.2) (±2.6) (±6.0) (±1.0) (±2.0) (±1.4) 
HF/TG 31.7 12.7 11.8 24.3 9.4t 6.0t 4.5t 
(±1.6) (±3.1) (±2.3) (±5.3) (±2.0) (±3.0) (±2.3) 
LF/EE 30.4 11.5 10.4 20.lt 11.2 9.7t 6.7t 
(±3.5) (±2.9) (±2.0) (±3.7) (±0.8) (±5.0) (±1.8) 
HF/EE 27.4 11.5 10.7 23.8t 10.2 10.4t 5.9t 
(±3.5) (±3.5) (±2.5) (±4.2) (±1.6) (±7.1) (±1.6) 
* Mean ± SEM; n=6 in each group. LFTG Oow fat triglyceride), HFTG (high fat triglyceride), LFEE 
Oow fat ethyl ester), HFEE (high fat ethyl ester). t Significantly different from baseline, P ~ 0.05 
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TABLE 11 
SERUM THROMBOXANE B2 (TxB2) AND THROMBOXANE B3 (TxB3) (nanograms/ml) FOR THE 
FOUR GROUPS AT BASELINE (BL), WEEK ONE (WKl) AND WEEK FOUR (WK4)* 
BASELINE WKl WK4 
TxB3 TxB2 TxB3 TxB2 TxB3 TxB2 
IF/TG 0.4 113.4 l.7t 68.5t§ 2.0t 66.5t 
(±0.1) (±15.2) (±0.2) (±9.1) (±0.4) (±19.2) 
HF/TG I 0.3 142.0 5.5t§ 109.3t 6.3t 76.1 t 
(±0.1) (±18.3) (±3.4) (±18.3) (±2.8) (±16.4) 
IF/EE I 0.2 111.3 l.2t 90.2 2.2t 57.1 t 
(±0.1) (±12. 7) (±0.2) (±11.4) (±0.6) (±5.2) 
HF/EE I 0.3 129.0 l.5t 89.7t 3.3t 63.3t 
(±0.1) (±18.5) (±0.3) (±21.4) (±0.9) (±19.0) 
•Mean± SEM. n=6. LFTG (low fat triglyceride). HFTG(high fat triglyceride). LFEE (low fat ethyl ester). HFEE (high fat ethyl 
ester) 
t Significantly different from baseline. P ~ 0.05. 
§ Significantly different from values at week I. P ~ 0.05. 
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TABLE 12 
URINARY PGI2-M AND PGI3-M (picograms/mg creatinine) FOR THE FOUR GROUPS DURING 
BASELINE (BL), WEEK ONE (WKl) AND WEEK FOUR (WK4)* 
BASELINE WKl WK4 
PGI3 PGI2 PGI3 PGI2 PGI3 PGI2 
LF/TG I <0.7 153.8 l l.4t 198.Bt 8.8t 127.8 
(±0.2) (±37.1) (±3.9) (±52.9) (±1.8) (±9.1) 
HF/TG I <0.8 127.9 22.3t§ 162.4t 12.6t 162.5 (±0.3) (±22.3) (±13.2) (±35.3) (±3.8) (±27.6) 
LF/EE I <0.5 128.0 7.6t 144.1 7.7t 136 .5 (±0.3) (±25.6) (±3.1) (±27.0) (±3.4) (±36.8) 
HF/EE I <0.6 119.8 9.2t 111.5 10.6t 131.1 (±0.2) (±25.8) (±2.1) (±22.5) (±5.3) (±18.1) 
• Mean± SEM. n=6 in each group. LFTG (low fat triglyceride. HFTG (high fat trtglycertde). LFEE (low fat ethyl eter) HFEE 
(high fat ethyl ester) 
t Significantly different from baseline, PS 0.05. 
§ Significantly different from values at week 1 PS 0.05 . 
DISCUSSION AND SUMMARY 
DISCUSSION OF RESULTS 
Previous studies have failed to provide con trolled dietary 
intervention for evaluating the effects of dietary fat on omega-3 fatty 
acid disposition. Because omega-3 fatty acid may be useful in certain 
types of vascular disease, we have attempted to define the most 
efficient and biochemically effective means to provide them to 
patients. In the present study the effects of a diet either low or high 
in fat with a constant amount of eicosapentaenoic acid (EPA) in two 
dosage forms was studied. We hypothesized that the effect of less 
"dilution" by other dietary fat, as in a low fat diet, might enhance EPA 
incorporation or conversion into eicosanoids. It has been reported 
that absorption of omega-3 fatty acids can be altered by both the 
dosage form and the total amount of fat consumed (139,185). 
To determine whether these parameters might alter the 
pharmacological effects of EPA in man, we administered omega-3 fatty 
acids providing approximately 4.8 grams per day of eicosapentaenoic 
acid (EPA) for four weeks as either triglycerides (TG) or ethyl esters 
(EE) to four groups (6 healthy males per group) whose diets contained 
either 20% or 40% of total calories derived from fat. All subjects were 
placed on a standardized run-in diet with 40% of calories from fat for 
two weeks prior to receiving omega-3 fatty acid supplementation. In 
order to monitor fat intake, analysis of three day food records were 
conducted. Biochemical measurements included fatty acid 
116 
incorporation into fasting plasma phospholipid, thromboxane B2 and 
thromboxane B3 generation of platelets during blood clotting ex vivo, 
and urinary 2,3 dinor metabolites(M) of PGI2 and PGI3 produced by 
the endothelium in vivo. 
One aim of this study was to evaluate the influence of the level of 
dietary fat on omega-3 fatty acid incorporation and conversion to 
eicosanoids by platelets and blood vessels. Eskimos had demonstrated 
an increase in omega-3 fatty acids in plasma lipids which apparently 
reflects their dietary pattern of high intakes of these long chain fatty 
acids, (approximately 5 to 10 grams per day), possibly for a lifetime. 
(38). In addition, the ratio of dietary omega-3 fatty acids to omega-6 
fatty acids found in dietary survey of seven Greenland Eskimos 
compared to typical Danish food was 0.95 to 0.07, respectively (90). 
The question remains as to the amount of omega-3 fatty acids required 
in the diet to alter in vivo eicosanoid formation. But a related question 
is whether it is the total amount of polyunsaturated fatty acids or a 
specific ratio of omega-3 to omega-6. In addition, the effectiveness of 
dietary omega-3 fatty acids in altering biological parameters such as 
eicosanoid synthesis, may depend not only on the amount of dietary 
omega-3 fatty acids but also on the reduction of dietary omega-6 fatty 
acids (31). 
Most clinical trials have used large doses of omega-3 fatty acids 
(>4 g per day) for a period of days or months to try and achieve a 
desired response. However, it seems that the desired responses 
maybe better achieved with small doses over a longer period of time to 
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simulate more closely the Eskimo diet rather than using high doses 
over a short term (119). A dose response study found only a small 
additional increase in plasma phospholipids when the dose was 
doubled from 3 to 6 grams per day of ethyl ester omega-3 fatty acids 
following a 12 week intervention period (186). This is in contrast to 
Harris et al who found an increase from 4 to 33% in plasma 
phospholipids following a fish diet containing 20-29 g of omega-3 fatty 
acids per day for four weeks (49). The required amount of omega-3 
fatty acids may vary depending on the desired response, e.g. the 
amount of omega-3 fatty acids needed to reduce the levels of plasma 
and cellular arachidonic acid and thromboxane formation appears to 
be lower than that required to decrease elevated triglycerides (92). 
A recent study in rats compared the ratio of dietary of omega-3 
fatty acids to omega-6 fatty acids to absolute amounts of omega-3 fatty 
acids on the degree of inhibition of eicosanoid biosynthesis from 
arachidonic acid (187). Their results showed that the ratio of omega-
3 to omega-6 may be the determining factor for inhibiting eicosanoid 
biosynthesis from arachidonic acid. In the present study, we achieved 
a dietary omega-3 to omega-6 ratio between 0.9 and 1.16 in both low 
fat groups compared to 0.4-0.5 in the high fat groups during the four 
week active intervention period, thus attempting to balance the 
endogenous thromboxane and prostacyclin synthesis optimizing the 
suppression of eicosanoids synthesized from arachidonic acid. We 
found a larger increase in PGI3 production in the HFrG group with 
the lower ratio. 
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The present study demonstrates through dietary instructions, 
counseling sessions and three day food record documentations, the 
compliance of subjects to a low fat diet (20% of calories). The major 
focus of the dietary instruction was 'fat gram counting'. This method 
had been employed in two studies designed to reduce dietary fat 
intake (188,189). The low fat diet groups (LFTG and LFEE}, were able 
to obtain substantial reductions from baseline values in percent of 
calories derived from fat, total fat grams, polyunsaturated 
monounsaturated and saturated fatty acids. The LFTG group exhibited 
about a three fold decrease in total fat grams, monounsaturated and 
saturated fats, with similar results seen in the LFEE group. In 
addition, both the low fat groups, (LFTG and LFEE}, achieved 
significantly lower levels of fat intake compared to the high fat groups, 
HFTG and HFEE, by the fourth week. An over two fold reduction in 
dietary omega-6 fatty acids in both low fat groups occurred in the 
present study while omega-3 fatty acids increased dramatically in all 
four groups with the fish oil supplementation. 
A number of important effects of twenty-carbon polyunsaturated 
fatty acids are related to their enzymatic conversion to highly potent, 
biologically active eicosanoids (84, 153). Our usual eicosanoids are 
synthesized from arachidonic acid either provided in the diet, less 
than 100 mg per day, or from an endogenous source, conversion in 
the liver from dietary linoleic acid (4). If dietary intake of arachidonic 
acid is low, then the concentration of arachidonic acid in tissue pools 
is influenced by the amount of dietary linoleic acid and the rate-
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limiting ~6 desaturase which converts linoleic acid into arachidonic 
acid (29, 37). In disease states, such as cardiovascular disease, with 
thrombosis, normal regulatory mechanisms may fail resulting in an 
excess production of eicosanoids, especially thromboxane A2, which 
has potent vasospastic and pro-aggregatory activities (4). 
In the cardiovascular system, the biosynthesis of thromboxane 
A2 appears to be concentrated in the platelets whereas prostacyclin is 
produced in the vascular wall; both share the same precursor, 
arachidonic acid(153). Thromboxane A2 is very potent in inducing 
the constriction of arterial smooth muscles in vivo and in vitro. In 
contrast prostacyclin has a vasodilatory effect. It has been proposed 
that the controlling mechanism for platelet aggregation is the balance 
between thromboxane A2 and prostacyclin formation in the 
cardiovascular system (190). Too much thromboxane A2 or too little 
prostacyclin may lead to thromboembolic disease. Thromboxane A2 
production appears to be increased in both experimental and human 
atherosclerosis (190). Thus an imbalance of these eicosanoids may 
predispose the atherosclerotic vessels to vasospasm and platelet 
aggregation in vivo. 
Dietary omega-3 fatty acids, in particular the longer chain ones 
in fish oils, may exert beneficial effects. These fatty acids can inhibit 
~6 desaturase and thus may reduce the conversion of linoleic to 
arachidonic acid. In addition to inhibiting this conversion, these fatty 
acid may competitively displace arachidonic acid from tissue 
phospholipid pools (37, 50, 55, 191). These two major influences will 
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result in reduced availability of arachidonic acid for eicosanoid 
production in a variety of cells. 
Another possible effect of increasing the omega-3 fatty acids in 
the diet involves the key enzyme in prostanoid synthesis, 
cyclooxygenase (4, 191). Arachidonic acid is the preferred substrate 
for this enzyme under in vitro conditions, and even though the omega-
3 fatty acids show a high affinity they are not as easily oxygenated in 
vitro as arachidonic acid (30). However, omega-3 fatty acids can 
suppress eicosanoid synthesis from arachidonic acid by competitively 
binding to the cyclooxygenase (192). This project showed a decrease 
in serum thromboxane B2 production but did not decrease in vivo 
PGI2-M excretion by healthy male subjects. 
If tissue EPA and DHA content is increased and if they are 
released concurrently with arachidonic acid by phospholipases, they 
can bind to the enzyme and thus inhibit eicosanoid synthesis. 
However, in platelets stimulated ex vivo with thrombin, 
docosahexaenoic acid (DHA) is not significantly released which is in 
contrast to EPA and AA (193) and as such might be too little to affect 
arachidonic acid metabolism. A kinetic study in man found that 
dietary DHA is retroconverted to EPA which is quickly transformed to 
PGI3 and, therefore DHA may serve as a precursor fatty acid for EPA 
and its cyclooxygenase products (194). This type of reaction may be 
enhanced if in addition to the increase of omega-3 fatty acids, 
especially EPA, there is a simultaneous reduction in the arachidonic 
acid as this study tried to achieve through dietary modification. 
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This type of dietary alternative would include sufficient 20 
carbon long-chain polyunsaturated fatty acids to suppress the 
overproduction of eicosanc;>ids derived from arachidonic acid. Also a 
total dietary fat reduction would be necessary to accommodate fatty 
acids ingested from fish or fish oil supplements. Lowering the fat 
intake of linoleate levels to recommended amounts (1-4% of daily 
calories) might permit even moderate amounts of fish oil to exert the 
desired beneficial effects (31). 
The dietary manipulation as well as compliance to fish oil 
supplementation can be evaluated by analysis of fasting plasma 
phospholipids. Previous studies had demonstrated an increase in both 
eicosapentaenoic acid and docosahexaenoic acid in plasma 
phospholipids following fish and fish oil supplementation regardless of 
overall dietary intake (5, 8, 48, 53, 64, 66, 69). The present study 
was designed to evaluate two factors that may influence omega-3 fatty 
acid incorporation: 1) the effects of a low fat or high fat diet; and, 2) 
the dosage form if omega-3 fatty acids were provided as either a 
triglyceride or an ethyl ester. 
The fatty acid profile of fasting plasma phospholipids in this 
study reflected the increase in dietary omega-3 fatty acids. Significant 
increases in the incorporation of EPA were found in all four groups 
following one week of fish oil supplementation and dietary 
manipulation with the largest increase found in the HFEE group. 
Week four also found significant increases for EPA compared to 
baseline in all four groups with the highest incorporation of EPA for 
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the ethyl ester groups. Incorporation of DHA was significantly 
different from baseline and week one in the HFEE group with all four 
groups displaying significant increases at week four. This larger 
incorporation into plasma phospholipids of EPA could be attributed to 
it's absorbability in conjunction with a high fat intake. 
Previous studies report conflicting results regarding the 
absorbability of the various forms of fish oil (85. 139. 146). It had 
been shown in 1965 that fish oil containing EPA and DHA were poor 
substrates for porcine pancreatic lipase (134, 135). Studies in rats 
have also demonstrated impaired absorption of fatty acids from fish oil 
compared to fatty acids from corn oil (195). Human studies have also 
given rise to similarly conflicting reports. An earlier report showed 
impaired absorption of low doses fish oil fatty acids depending on the 
dosage form (139) with a more recent study finding similar absorption 
between high doses of the ethyl ester form and triglyceride forms 
(196). 
Boustani et al reported EPA incorporation into plasma 
triglyceride was markedly smaller and later when EPA was 
administered as an ethyl ester compared to free fatty acid ( 138). 
When one gram of EPA was administered as ethyl ester. the increase 
of EPA into plasma triglycerides was three times less and occurred at 
least three hours later compared to the other three forms of omega-3 
fatty acids; free fatty acid. triglyceride and arginine salts (139). It was 
suggested that this difference may result from impairments at the EPA 
123 
ethyl ester hydrolysis step, at the EPA absorption step or an unknown 
process involved in polyunsaturated fatty acid absorption. 
The results in the present study showing a lower incorporation 
into fasting plasma phospholipids of the triglyceride form compared to 
ethyl ester form may be attributed to reduced activity of pancreatic 
lipase towards the triglycerides containing EPA. This type of reduced 
activity in pancreatic lipase has been demonstrated in vitro (197). 
Lipase activity on o_ctadecenoates is reduced in which the double 
bonds are present in the third to the sixth position from the carboxyl 
end of the molecule. DHA and EPA with double bonds in the position 
4 and 5, respectively, may experience reduced lipase activity and thus 
may have reduced absorption. In addition, Bottino demonstrated that 
this resistance to lipolysis by porcine pancreatic lipase may be 
independent of the triglyceride fatty acid position on the molecule 
( 135). 
Although there are no direct studies of the efficiency of lipolysis 
of triglycerides containing omega-3 fatty acids in humans, it was 
reported that a reduction occurred in post-prandial 
hypertriglyceridemia in subjects fed a fatty meal containing salmon oil 
( 198). This may indicated a slower rate of lipolysis of the omega-3 
containing triglyceride in the intestines. It is suggested that once 
triglycerides containing omega-3 fatty acids are hydrolyzed, the 
omega-3 fatty acids are totally absorbed in vivo and apparently 
metabolized like other fats ( 130). 
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On the other hand, ethyl ester absorption appears to be different 
compared to the triglyceride. There has been no assurance that ethyl 
esters are hydrolyzed by pancreatic lipase as efficiently as natural fat. 
However, eicosapentaenoic acid from ethyl ester appears to be totally 
absorbed, but by two different routes, the lymphatic system and portal 
system depending upon the efficiency of hydrolysis and incorporation 
of the fatty acids into triglycerides. 
Further evaluation of the sluggish intestinal activity towards 
esterified EPA and DHA was undertaken in conjunction with a high fat 
meal, 44% of calories from fat ( 185). Co-ingestion of a high fat meal 
with fish oil supplementation improved the absorption for both the 
triglyceride form of EPA and the ethyl ester forms of both EPA and 
DHA 
The high fat meal appears to increase pancreatic lipase activity, 
most likely including an effect to increase bile secretion, resulting in 
an increased absorption of omega-3 from fish oil fatty acids. This 
present study is in agreement as depicted by a similar higher increase 
of incorporation of EPA into fasting plasma phospholipids of the HFEE 
group. More specifically, our results indicate a trend of higher 
incorporation of EPA from both ethyl ester groups at week one and 
slightly higher at week four than in both triglyceride groups. DHA 
incorporation in the high fat ethyl ester group at week one was the 
only significant value found to be increased compared to baseline with 
all four groups achieving a significant increase by week four. 
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A wide range of reports exists regarding the effects of dietary 
omega-3 fatty acids on lipids and lipoproteins (3). With all of the 
studies conducted over the past several years evaluating these effects, 
only the reduction of plasma triglycerides can consistently be 
attributed to omega-3 fatty acids (3). Many variables affect the 
outcomes of these studies: the amount of fish oil per day, dosage form, 
study duration and other dietary factors. The present study found a 
statistically significant reductions in values from baseline to week one 
for all four groups (P <0.05) with a continued significant reduction at 
week four for the HFEE. However, trends were noted in the other 
lipid measurements. Total cholesterol values showed a decrease in all 
four groups from baseline values. The two low fat groups 
demonstrated the most reduction ( LFI'G, 6% and LFEE, 15%). LDL 
also demonstrated more of a reduction in the low fat groups than the 
high fat groups. This is probably due to the significant reduction in 
the saturated fat (as reflected in the food records) and is consistent 
with other published data (199). 
Obvious factors involved in the variability in response to lipid 
changes and omega-3 fatty acids are the type of patient being studied 
and dietary intervention, in particular the amount of saturated fatty 
acids present in the diet (3). Hypertriglyceridemic patients 
demonstrated a decrease in total cholesterol levels while 
hypercholesterolemic patients and normal subjects generally did not. 
The decrease in total cholesterol found in hypertriglyceridemic 
subjects was due to the fall in VLDL-C rather than LDL-C. It appears 
126 
that LDL-C levels increase primarily in patients with elevated VLDL-C 
levels and as such the rise in LDL-C is likely to result from enhanced 
LDL-C synthesis from VLDL-C. 
Other factors in the diet may affect the response of lipid 
parameters to omega-3 fatty acids When a control diet has more 
saturated fat than the fish oil diet, LDL-C will more likely be lower on 
the fish oil diet (3). As a result, fish oil was given the credit for 
reduction of cholesterol rather than a reduction in saturated fats. In 
normolipidemic patients similar outcomes were found. It appears that 
when saturated fat is held constant LDL-C levels tend to rise, while the 
lowering of saturated fat during fish oil supplementation results in a 
reduction of LDL-C. 
HDL-C levels have been shown to vary in their response to 
omega-3 fatty acid supplementation. Some studies reflect no change 
(16, 58, 69, 200) where as some show a decrease (44, 64) and others 
show an increase (50, 66, 201). This study resulted in fairly 
consistent values from baseline to week four for all four groups 
regardless of fat intake or dosage form. Whether omega-3 raised, 
lowers or does not affect HDL still remains to be determined. 
Data from the present study is in agreement with previous 
studies by showing a reduction in fasting triglyceride levels in normo-
triglyceridemic patients (5, 48, 49, 51, 52, 76, 82). The largest 
reduction was found in the high fat groups (HFTG 23% and HFEE 
35%) compared to the low fat groups (LFTG, 16% and LFEE, 15%). 
Most workers (3) feel that omega-3 fatty acids decrease triglyceride 
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synthesis by liver and the gastrointestinal tract. This reduction of 
plasma triglycerides in the high fat groups may also suggest an 
increase lipoprotein lipase activity following the ingestion of omega-3 
fatty acids with a high fat meal thus allowing for the increased rapidity 
of absorption of omega-3 fatty acids. Activity of lipoprotein lipase 
(LPL) was evaluated in adipose tissue, skeletal and heart muscle of rats 
consuming diets containing fish oil, com oil and tallow (202). Notably 
the fish oil group had the highest LPL activity in both heart and 
skeletal muscles . The increased LPL activity may contribute the 
triglyceride lowering effect of fish oil. 
Studies on healthy volunteers (5, 48), patients with coronary 
atherosclerosis ( 1 7) or peripheral atherosclerosis ( 15) have all 
demonstrated prolonged bleeding times following high dose 
supplementation with omega-3 fatty acids (> 3 g EPA/day). In contrast 
to these studies, hyperlipidemic patients (66, 203) and one study of 
healthy individuals demonstrated no change in bleeding times (82). 
Our study on healthy male subjects detected only one group (LFrG) 
which demonstrated a significant (P< 0.05) prolonged bleeding time 
following four weeks of supplementation of 4.8 grams EPA per day. 
Three groups, (LFTG, HFTG, and HFEE) all had slight reductions in 
bleeding times following one week of fish oil supplementation. An 
increase in the amount of fish oil or prolonging the study duration may 
increase and/or prolong bleeding times. 
In contrast to studies showing no increase in bleeding times in 
healthy subjects, Lorenz et al demonstrated increased bleeding times 
128 
in healthy males receiving 40 ml of cod liver oil to an otherwise 
unchanged Western diet (3 g EPA and 5 g DHA) (5). The longer 
bleeding time may be due to a decrease in pro-aggregatory 
thromboxane and an increase in anti-aggregatory prostacyclin. In 
addition, bleeding time is highly susceptible to observer bias and 
demonstrates a great deal of variability between individuals (204). 
Studies by Dyerberg and Bang found prolonged bleeding times in 
the Greenland Eskimo population which was attributed to the higher 
fish content in the diet and to the substitution of arachidonic acid with 
eicosapentaenoic acid in tissue lipids (40). Further investigation found 
evidence that the hemostatic function of the Eskimos was dominated 
by anti-aggregatory prostaglandins derived from eicosapentaenoic acid 
as compared to the metabolites from arachidonic acid (205). The 
effects of eicosapentaenoic acid on hemostatic function is associated 
with a reduced production of the predominat arachidonate product, 
thromboxane A2 (204). 
The extent to which physiological hemostasis depends on 
prostaglandins remains unclear. Thorngren et al studied the 
contribution of thromboxane to primary hemostasis of healthy subjects 
in vivo (206). Measurements included thromboxane A2 from skin 
bleeding times and production during in vitro clotting of venous blood. 
Results indicated that during the bleeding time the thromboxane A2 
increased, but as the rate of blood loss fell the thromboxane A2 
remained constant. When the subjects were grouped according to 
bleeding times, subjects with the shortest times had more 
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thromboxane A2 than those with longer bleeding times. The clotted 
venous blood in vitro produced much more thromboxane A2 than 
those with longer bleeding times and there was no correlation with 
bleeding time. As such the determination of thromboxane A2 from 
clotted blood in vitro is irrelevant to in vivo hemostasis. 
A report on volunteers consuming a fish diet found no change in 
bleeding times following one week of the diet despite changes of 
increases omega-3 and decreases in omega-6 in platelet phospholipids 
(207). A significant increase in bleeding time occurred at week six 
and continued to remain increased three weeks following the 
discontinuance of the diet, even when the fatty acid composition of 
the platelets returned to normal. The diet did not change the in vivo 
appearance of thromboxane A2 in the bleeding time blood, but caused 
a decrease in the in vitro formation in clotting venous blood. 
These two studies indicate that thromboxane A2 may play only a 
minor role in primary hemostasis as reflected in the template 
bleeding time. Our study found that the bleeding time was not closely 
related to thromboxane B2 inhibition. The data on hemostatic 
function suggest considerable variability of response and in some cases 
reports are conflicting. However, it appears that the platelet 
inhibitory effects of eicosapentaenoic are dependent on prevention of 
thromboxane A2 formation. 
This study also showed a significant reduction in serum TxB2 
generation in three of the four groups following one week of fish oil 
supplementation. The LFTG group demonstrated the biggest 
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reduction in TxB2 (38% vs 19%, 23% and 30%) and had the largest 
increase and most prolonged bleeding time at week four by which 
time all groups had similar TxB2 reductions (40% vs 46%, 48%, and 
50%). Thus it appears that the increase in bleeding time was not 
closely correlated to the TxA2 inhibition as previously discussed. 
The HFTG group produced more serum TxB3 at week one 
compared to baseline and than the other three groups, who also had 
significant but smaller increases from baseline. This initial increase in 
serum TxB3 production may be reflective of EPA being delivered to 
the platelet-vascular interface as a bolus of EPA-enriched lipoproteins 
being processed during post-prandial lipemia. A continued increase in 
TxB3 in all four groups was seen by week 4. This study demonstrated 
a continued increase in TxB3 production concurrent with a continued 
reduction in TxB2 on a 4.8 gram per day dose of EPA. Similar to these 
results, atherosclerotic patients and hypertensive patients also 
demonstrated a decline in TxA2 and concurrent formation of TxA3 
following supplementation with omega-3 fatty acids (9, 15). In 
contrast to these results, von Schacky and Weber found no change in 
production of immunoreactive TxB2 / 3 in clotted blood after 
supplementation with either 6 grams of EPA or DHA for six days (79). 
These results may be reflective of a short study duration. An earlier 
study of longer duration found a reduction of TxB2 and 
immunoreactive 1'xB2/3 as measured by the same test (55). Generally 
2-3 weeks of administration of a fixed dose is required prior to 
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attaining steady state in plasma and several months may be necessary 
for tissue lipid accumulation (204). 
The excretion of the PGI3 metabolite was increased at week one 
the largest increase found in the HFTG (22.3 vs 7.6, 9.3 11.2 pg/mg 
creatinine). Values declined at week four for the LFTG and HFTG 
group, with slight increases in the LFEE and HFEE groups. The HFTG 
group values still remained larger at week four (12.6 vs 7.7, 8.8, 10.6 
pg/mg creatinine). 
The results of the present study are in some ways similar to 
results on PGI2 production following fish and fish oil supplementation 
from previous reports (9, 15). PGI2 synthesis was increased at week 
one in three of the four groups following fish oil supplementation (4.8 
g EPA). The LFTG group exhibited the largest increase (29% P ~ 0.05) 
from baseline values followed by the HFTG group (27% P~ 0.05). By 
week four the LFTG and LFEE values were returning to baseline levels, 
while the HFTG remained unchanged. The HFEE group increased 
from baseline measurements by week four of supplementation. This 
increase may be reflective of the larger incorporation of EPA into the 
plasma phospholipids for HFEE at week four. 
In contrast to healthy subject used in this study, atherosclerotic 
patients exhibit a baseline excretion of PGI2 significantly elevated 
from those of healthy age-matched controls (15). The atherosclerotic 
patients demonstrated a decrease in PGI2 following fish oil ingestion 
with a continued decrease throughout the study period. This 
reduction may be attributed to a reduction in platelet vessel wall 
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interaction. Healthy volunteers compared to atherosclerotic patients 
did not exhibit a depressed production of PGI2 which is similar to our 
study. 
PGI3 was found to have increased in both the atherosclerotic 
patients and healthy volunteers which was found in the present study. 
Also these results are in agreement with Fischer and Weber who 
reported that PGI2 biosynthesis was unaltered during formation of 
PGI3 in volunteers placed on a high fat diet (77). 
A study involving hypertensive patients evaluated the effects of a 
low dose of fish oil, (1.8 g EPA and 1.2 g DHA) and a high dose of fish 
oil (9.0 g of EPA and 6.0 g DHA) on hypertension and metabolic 
parameters for four weeks (9). There was no control over the diet 
except patients were asked to watch fat intake in order to remain 
weight stable. The high dose group had the largest increase in PGI2 
and PGI3 following one week of supplementation. A decline in PGI2 
and PGI3 occurred over the next three weeks of the study. Even 
though there was an _overall decrease by week four compared to the 
elevated values at week one, PGI3 was 27% of the total prostacyclin 
production. The normotensive control group also demonstrated an 
initial increase in production of PGI3 following week one of 
supplementation. In subjects taking the low dose of fish oil, PGI3 was 
produced but in smaller amounts. 
The study on hypertensive patients indicates that an 
unrestricted diet, in conjunction with a high dose of fish oil, results in 
an increase of prostacyclin production over a low dose of fish oil. Our 
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present study demonstrates that a high fat diet (40% of calories) plus 
4.8 grams of EPA in triglyceride form induced the greatest production 
of PGI3. Despite similar omega-3 fatty acid incorporation in the 
plasma phospholipids at week one, more conversion of EPA occurred 
in the HFTG group for PGI3 (mean 21.5 vs 10.7, 7.1, and 8.6 pg/mg 
creatinine). 
The results from our study provides additional evidence that fish 
oil, 4.8 gram per day of EPA leads to in vivo production of PGI3. One 
study found that EPA appears to have an inhibitory effect on PGE2 
synthesis and is converted to trivial amounts of PGE3 in vivo (208). It 
has been speculated that under conditions of high cyclooxygenase 
activity as found in seminal vesicles in vivo, EPA is a poor substrate for 
prostaglandin production. However if a much lower rate of enzyme 
activity is present such as in the endothelium in vivo, eicosapentaenoic 
acid may be as good a precursor as arachidonic acid for prostaglandins 
as demonstrated by PGI2 and PGI3 production. 
Even with similar amounts of EPA available, we found that the 
greatest PGI3 production resulted when the EPA was provided with a 
greater amount of dietary fat, since EPA provided in triglycerides 
appear to form greater amounts of EPA enriched lipoproteins. Such 
enriched chylomicrons will be processed and hydrolyzed by the 
endothelium during post-prandial lipemia, and it may be at this time 
that the potential benefits of EPA on vascular disorders are exerted. 
These results, therefore, suggest another metabolic pool for 
prostaglandin precursor fatty acids in addition to membrane 
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phospholipids which would be readily available for eicosanoid 
production. This type of precursor availability is directly related to 
dietary manipulation with omega-3 fatty acids and does not depend on 
the release of the fatty acid from the phospholipids of cell membranes. 
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SUMMARY AND CONCLUSION 
No study to date has evaluated EPA disposition on a strict fat 
controlled diet utilizing two forms of EPA, triglyceride or ethyl ester. 
This present study supplied an equal amount of EPA. (4.8 grams) to a 
diet providing either 20% of calories derived from fat or 40% of 
calories derived from fat. The traditional Eskimo diet provided a 
relative high fat intake with the major source of fat relatively enriched 
in omega-3 fatty acids. The high fat intake in conjunction with a large 
amount of omega-3 fatty acids may be one of the cardio-protective 
factors found in this population. 
The diet in industrialized Western countries contains a high 
proportion of fat having a high omega-6 fatty acid and low omega-3 
fatty acid content and is associated with the highest incidence of 
cardiovascular disease in these countries. Our prehistoric and historic 
ancestors may have suffered a lower incidence of chronic disease such 
as cardiovascular disease and cancer, and had a nutrient intake low in 
fat and relatively rich in omega -3 fatty acids. Our study investigated 
the effect of varying dietary fat at a constant intake of omega-3 fatty 
acids (utilizing two different dosage forms) on biochemical parameters 
which may be related to the development of atherosclerosis. 
We have demonstrated in this study the ability to achieve two 
levels of fat intake, low fat and high fat, in order to assess the effect of 
total dietary fat and EPA dosage form on the serum thromboxane 
production and prostacyclin production from both arachidonic and 
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eicosapentaenoic acids. Despite similar amounts of omega-3 fatty 
acids incorporated into the fasting plasma phospholipids at week one, 
the TGHF group had the largest conversion into TxB3 and PGI3. 
Conversion of the the EPA provided as ethyl ester into PGI3 and TxB3 
appeared to take a longer time. This was associated with a higher 
degree of EPA incorporation in fasting plasma phospholipids at week 
four. However, the levels of EPA derived eicosanoids achieved at week 
four by the EE groups did not achieve those reaching the TGHF group 
at week one. These results may indicate that more TxB3 and PGI3 
may be formed if eicosapentaenoic acid is provided in conjunction 
with a higher fat intake compared to a lower fat intake. This would 
result in greater amounts of EPA-enriched chylomicrons and may 
suggest that post-prandial lipoprotein processing provides eicosanoid 
precursors directly to activated platelets and endothelium. 
Most studies have dealt with the effects of dietary fat on fasting 
blood levels even though most of our lives are spent in a post-prandial 
state (208). This condition allows for increased exposure of the vessel 
walls to these fat enriched lipoproteins, in particular chylomicrons 
and chylomicron remnants. Speculation has arisen regarding the 
potential atherogenicity of these types of particles and their 
contribution in the development of the atherosclerotic lesion. 
The hypothesis has been advanced that chylomicrons in persons 
who consume a high fat, cholesterol-enriched diet may be atherogenic 
and contribute to the early manifestations of arterial pathology (210). 
Chylomicrons are the principal carriers of dietary fat and cholesterol 
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in the blood stream and the first stage of their degradation takes place 
in contact with the vascular endothelium. Chylomicrons can be 
converted to chylomicron remnants following hydrolysis by lipoprotein 
lipase. This process involves the binding of chylomicrons to the 
arterial surface, possibly to the subendothelial sites exposed by loss of 
endothelium which occurs in most capillary beds and could take place 
in the arterial endothelium and smooth muscle cells. These 
remaining remnants can be incorporated into the cells of the vascular 
endothelium by endocytosis. The incorporation of the chylomicron 
remnants into the endothelium could be a major contributing factor 
affecting atherosclerosis and thrombosis, and might be influenced by 
the availability of prostaglandin precursor fatty acids present. 
Weintraub et al indicated that substitutions of omega-6 fatty 
acids and even more so of omega-3 fatty acids for saturated fatty acids 
can result in a reduction in post-prandial lipoprotein levels (209). 
They evaluated post-prandial lipemia with acute fat loads in patients 
with chronically modified dietary fat. It appears that the strongest 
influence on the post-prandial lipoprotein levels was the type of 
polyunsaturated fatty acids, omega-6 and omega-3, present in the fat 
chronically ingested. Our study found the greatest reductio~ in 
triglyceride levels at week one for the HFTG group and at week four 
for the HFEE group. This demonstrates that a high fat intake in 
conjunction with a fixed dose of EPA can enhance incorporation of 
omega-3 fatty acids into metabolically important cell pools. 
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Absorption of fish oil omega-3 fatty acids, triglyceride or ethyl 
ester, was evaluated based on co-ingestion of a high fat meal (44% of 
calories from fat) by Lawson and Hughs (185). The absorption of low-
dose ( 1 gram) EPA from triglyceride was increased significantly, (69 
to 90%), by co-ingestion of the high fat meal but DHA absorption was 
not dramatically improved. This lack of improvement may be due to 
the resistance of the triglyceride to lipase hydrolysis when the fatty 
acid contains a double bond in one of the six positions nearest the 
carboxyl-end. Absorption of low-dose · EPA given as ethyl esters 
however, was increased three fold which is suggestive of an increased 
pancreatic lipase activity. The absorption of ethyl ester fatty acids 
does not appear to be affected by the position of their double bonds. 
Even though our study did not evaluate the post-prandial lipoprotein 
levels, it is suggestive of a distinct effect of a high fat intake in 
conjunction with omega-3 fatty acids compared to the low fat levels. 
The HFTG group demonstrated the greatest increase in both TxB3 and 
PGI3 formation which may be beneficial in establishing an anti-
aggregatory, vasodilatory environment thus influencing the 
pathophysiology for the development of atherosclerosis. 
In conclusion, additional clinical studies are needed to evaluate 
the effects of individual fats, (such as EPA and DHA) on post-prandial 
lipoprotein composition and metabolism. In addition to the individual 
fats, the dosage form needs to be carefully evaluated. Studies should 
be designed to account for the variation in absorption and 
atherogenicity of lipoprotein particles, such as chylomicron remnants, 
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and the influence of the amounts of dietruy fats on these specific post-
prandial lipoproteins. The significant reduction in post-prandial 
lipoproteins resulting from omega-3 fatty acids in conjunction with 
the formation of anti-aggregatory /vasodilatory metabolites indicate that 
the omega-3 fatty acids may have a potential of becoming therapeutic 
agents for the reduction of cardiovascular disease in specific clinical 
settings. This study further indicates that the clinical promise for 
omega-3 fatty acids may be influenced by both their dosage form as 
well as total dietary fat, and that these parameters should be 
considered in future studies for developing therapeutic modalities 
towards the amelioration of cardiovascular disease and its thrombotic 
complications. 
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